[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 245
1. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A: Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol; 2006 Aug;19(8):1101-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified.
  • The germinal center T-helper cell has been proposed as the cell of origin for angioimmunoblastic T-cell lymphoma.
  • Our recent report of expression of CXCL13, a chemokine critical for germinal center formation and one of the most highly upregulated genes in the germinal center T-helper cell subset, in the majority of angioimmunoblastic T-cell lymphoma cases, provided further support for this theory.
  • To determine the specifity of this marker for angioimmunoblastic T-cell lymphoma, we evaluated CXCL13 expression in 26 nodal-based peripheral T-cell lymphomas and 14 lymph nodes showing paracortical lymphoid hyperplasia.
  • By WHO classification criteria, 20 of the lymphoma cases were considered peripheral T-cell lymphoma, unspecified, and six were reclassified as angioimmunoblastic T-cell lymphoma after immunohistochemical detection of disorganized follicular dendritic cell meshworks.
  • Combining the results of our studies, 31 of 35 angioimmunoblastic T-cell lymphoma cases (89%) showed CXCL13 expression, in contrast to two out of 20 peripheral T-cell lymphoma, unspecified cases (10%).
  • The two peripheral T-cell lymphoma, unspecified cases that were positive for CXCL13 showed a Lennert lymphoma-like histology.
  • While these cases did not meet all histologic criteria for angioimmunoblastic T-cell lymphoma, they did show an increase in EBV-positive B cells, suggesting they may be histologic variants of angioimmunoblastic T-cell lymphoma.
  • In conclusion, CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm.
  • Given its specificity when compared to cases of peripheral T-cell lymphoma, unspecified as well as paracortical lymphoid hyperplasia, it may be a useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chemokines, CXC / metabolism. Germinal Center / metabolism. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes, Helper-Inducer / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chemokine CXCL13. Diagnosis, Differential. Humans. Pseudolymphoma / metabolism. Pseudolymphoma / pathology. Up-Regulation


2. Lin O, Filippa DA, Teruya-Feldstein J: Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall. Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall.
  • Cases of CD45-negative acute lymphoblastic lymphoma/leukemia (ALL) immunoreactive for CD99 and Friend Leukemia Integration-1 (FLI-1) can occur and may lead to a misdiagnosis of Ewing sarcoma/peripheral neuroectodermal tumor with critical clinical treatment management implications.
  • The objective of this study was to evaluate a panel of antibodies that would allow greater diagnostic accuracy of ALL and evaluate the frequency of FLI-1 immunoreactivity in a series of ALL cases and an expanded series of T-cell lymphoma subtypes.
  • Therefore, CD43 and/or TdT should be included in the immunohistochemical evaluation of small round blue cell tumors.
  • Absence of immunoreactivity for LCA does not exclude ALL and immunoreactivity of FLI-1 is not restricted to Ewing sarcoma/peripheral neuroectodermal tumor.
  • We also report FLI-1 expression in an expanded series of 75 cases of T-cell lymphoma and found high expression in anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349856.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FLI1 protein, human; 0 / Proto-Oncogene Protein c-fli-1
  •  go-up   go-down


3. Welch KD, Reilly TP, Bourdi M, Hays T, Pise-Masison CA, Radonovich MF, Brady JN, Dix DJ, Pohl LR: Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem Res Toxicol; 2006 Feb;19(2):223-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice.
  • Drug-induced liver disease (DILD) continues to cause significant morbidity and mortality and impair new drug development.
  • Mounting evidence suggests that DILD is a complex, multifactorial disease in which no one factor is likely to be an absolute indicator of susceptibility.
  • As an approach to better understand the multifactorial basis of DILD, we recently compared the hepatic proteomes of mice that were resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD) wherein we identified potential risk factors and mechanistic pathways responsible for DILD.
  • In this study, we have uncovered additional potential risk factors by comparing hepatic mRNA expression profiles of the same two strains of mice with that of SJLxB6-F1 hybrid (F1) mice, which were found to be of intermediate susceptibility to AILD.
  • One of these genes encoded for heat shock protein (HSP) 70 whose relative protein expression among the three strains of mice was found to parallel that of their mRNA levels, suggesting that this protein had a protective role against AILD.
  • However, there was no difference in the susceptibility of HSP70 knockout (KO) mice to AILD as compared to wild-type (WT) mice.
  • In support of this hypothesis, OPN KO mice were found to be more resistant to AILD than WT mice.
  • [MeSH-major] Acetaminophen / toxicity. Drug-Induced Liver Injury. Genetic Predisposition to Disease. Liver Diseases / genetics

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485898.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


Advertisement
4. Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH: Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol; 2008 Dec;68(3):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms, lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia.
  • The neoplastic CD4+ T-cells represent a minority of the lymph node cell population; its detection is facilitated by the aberrant expression of CD10.
  • Almost all cases arbor an EBV infected B-cell population.
  • Patients with AITL have a poor prognosis with conventional treatment, with a median overall survival of less than 3 years.
  • Patients achieving a good clinical response seem beneficiate from a consolidation with high-dose therapy and autologous stem cell transplantation.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Lymphoma, T-Cell / drug therapy. Stem Cell Transplantation. Thalidomide / therapeutic use
  • [MeSH-minor] B-Lymphocytes / metabolism. B-Lymphocytes / pathology. B-Lymphocytes / virology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Cell Proliferation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / mortality. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / therapy. Female. Herpesvirus 4, Human. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Neprilysin / metabolism. Survival Rate. Transplantation, Autologous

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684638.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 57
  •  go-up   go-down


5. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH: Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom; 2006 May;70(3):142-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric features of angioimmunoblastic T-cell lymphoma.
  • BACKGROUND: The immunophenotypic features of angioimmunoblastic T-cell lymphoma (AILT) have not been well described.
  • METHODS: We retrospectively reviewed our institutional experience with the flow cytometric features of 16 cases of AILT.
  • CD10 was expressed by the neoplastic populations in 11 of 14 cases at diagnosis; in 3 of these 11 only a subpopulation of the neoplastic cells was CD10(+).
  • CONCLUSIONS: These results indicate the potential utility of flow cytometry in the diagnosis and follow-up of AILT.
  • [MeSH-major] Flow Cytometry / methods. Immunoblastic Lymphadenopathy / pathology. Immunophenotyping / methods. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD3 / analysis. Antigens, CD45 / analysis. Antigens, CD7 / analysis. Bone Marrow / pathology. Female. Follow-Up Studies. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / analysis. Receptors, Complement 3d / analysis. Retrospective Studies. T-Lymphocytes / chemistry. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16572417.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD7; 0 / Receptors, Complement 3d; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. Martin JE, Wagner AJ, Murphy GF, Pinkus GS, Wang LC: Granuloma annulare heralding angioimmunoblastic T-cell lymphoma in a patient with a history of epstein-barr virus-associated B-cell lymphoma. J Clin Oncol; 2009 Nov 1;27(31):e168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granuloma annulare heralding angioimmunoblastic T-cell lymphoma in a patient with a history of epstein-barr virus-associated B-cell lymphoma.
  • [MeSH-major] Granuloma Annulare / complications. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / complications. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Granuloma Annulare.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770367.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Iqbal MH, Smith PR, Bande S: Chylothorax due to angioimmunoblastic T-cell lymphoma. Intern Med J; 2009 Jan;39(1):67-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chylothorax due to angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chylothorax / etiology. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19290988.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


8. Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, Sanger WG: Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol; 2008 May;141(4):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
  • Cytogenetic correlations among most types of peripheral T-cell lymphoma (PTCL) have not been very informative to date.
  • This study aimed to identify recurrent chromosomal abnormalities in angioimmunoblastic T-cell lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALK-ALCL) and peripheral T-cell lymphoma, unspecified (PTCL-US), and to evaluate their prognostic value.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell, Peripheral / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Immunoblastic Lymphadenopathy / genetics. Karyotyping. Lymphoma, Large-Cell, Anaplastic / genetics. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341637.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


9. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A: CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol; 2005 Jul;36(7):784-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry.
  • Angioimmunoblastic T-cell lymphoma (AITCL) is a histologically distinct and relatively common subtype of T-cell lymphoma.
  • Although the putative normal cell counterpart is a mature CD4+ T cell, the precise cell of origin remains elusive.
  • We evaluated cases with a diagnosis of AITCL to determine the specificity and utility of CD10 coexpression, particularly by flow cytometry (FCM), in facilitating this diagnosis.
  • Four cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), were also analyzed.
  • The lymphoma cells in all 8 AITCL cases were CD4+, CD45RO+ T cells, with classic extrafollicular meshworks of CD21/CD23/CD35+ follicular dendritic cells.
  • CD10 coexpression was not observed in all 4 PTCL-NOS cases.
  • Although not specific for AITCL, increased numbers of BCL6+ cells were seen in AITCL as compared with PTCL-NOS.
  • The finding suggests that AITCL may be a neoplasm of (possibly intrafollicular) CD10+, BCL6+, and CD4+ memory T cells.
  • Although our series is small, our results suggest that CD10 coexpression may be a useful discriminant, particularly if the differential diagnosis is PTCL-NOS, and demonstrate that this can be determined by FCM.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Flow Cytometry. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Neprilysin / metabolism. T-Lymphocytes / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Antigens, CD45 / metabolism. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Cell Count. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Lymphoma, T-Cell, Peripheral / metabolism. Lymphoma, T-Cell, Peripheral / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084948.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


10. Troxell ML, Schwartz EJ, van de Rijn M, Ross DT, Warnke RA, Higgins JP, Natkunam Y: Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma is characterized by a paracortical proliferation of medium to large neoplastic T cells, often with clear cytoplasm, in a background of arborizing high endothelial venules, many surrounded by follicular dendritic cells (FDCs).
  • The authors stained a collection of 45 angioimmunoblastic T-cell lymphomas with CD21, CD23, CNA.42, cystatin A, and fascin for direct comparison of FDC staining characteristics in this setting.
  • CD21 highlighted the expected dendritic network of cell processes, within residual follicles and outside of follicles, often adjacent to proliferating vessels.
  • Cystatin A stained the cytoplasm of follicular dendritic cells within and outside of follicles; however, staining was often not sharply localized to dendritic cell processes, and scoring was further complicated by reactivity with other cell types in over half of the cases.
  • Likewise, fascin stained a variety of cell types, including strong staining of interdigitating dendritic-like cells, moderate staining of endothelial cells, and only weak staining of follicular dendritic cells within and outside of follicles.
  • Thus, CD21 remains the most reliable marker of follicular dendritic cells in angioimmunoblastic T-cell lymphoma.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280657.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 146808-54-0 / fascin
  •  go-up   go-down


11. Karube K, Suzumiya J, Okamoto M, Takeshita M, Maeda K, Sakaguchi M, Inada T, Tsushima H, Kikuchi M, Ohshima K: Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases. Am J Surg Pathol; 2007 Feb;31(2):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases.
  • In adult T-cell lymphoma/leukemia (ATLL), the neoplastic lymphoid cells are usually medium-sized to large, often with pronounced nuclear pleomorphism compatible with the diagnosis of diffuse pleomorphic peripheral T-cell lymphoma.
  • We describe here 11 patients with the rare morphologic variant of ATLL, angioimmunoblastic T-cell lymphoma (AILT)-like type.
  • The lymphoma cells were medium-to-large size with clear cytoplasm.
  • These findings were suggestive of AILT.
  • However, immunohistochemical features of AILT, namely, CD10 and CXCL13 expression in lymphoma cells and proliferation of CD21-positive follicular dendritic cells, were not detected.
  • All patients were positive for antiadult T-cell leukemia/lymphoma-associated antigen, which is a specific antibody for human T-cell lymphotropic virus type-I.
  • Southern blot analysis revealed proviral DNA integration in lymphoma cells in 9 patients.
  • This is the first report of ATLL with AILT-like morphologic features.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255766.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Viral
  •  go-up   go-down


12. Qubaja M, Audouin J, Moulin JC, Molina TJ, Le Tourneau A, Gaulard P, Straub P, Audhuy B, Diebold J: Nodal follicular helper T-cell lymphoma may present with different patterns. A case report. Hum Pathol; 2009 Feb;40(2):264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal follicular helper T-cell lymphoma may present with different patterns. A case report.
  • We report the case of a 62-year-old patient presenting with 3 different patterns of follicular helper T-cell lymphoma.
  • The patient initially presented with angioimmunoblastic T-cell lymphoma.
  • A nodal relapse in the form of follicular T-cell lymphoma with a progressively transformed germinal center pattern occurred 8 years later.
  • Two years later, this was followed by another relapse presenting as a predominantly large-cell peripheral T-cell lymphoma, unspecified.
  • The immunophenotype showed a progressive increase in the proportion of cells expressing CD10, bcl-6, CXCL13, and programmed death-1 from the first to the last lymphoma.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. T-Lymphocytes, Helper-Inducer / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760445.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Baseggio L, Berger F, Morel D, Delfau-Larue MH, Goedert G, Salles G, Magaud JP, Felman P: Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia; 2006 Feb;20(2):296-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.
  • In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques.
  • Here, we evaluated if the analysis of blood smears may suggest the blood dissemination of angioimmunoblastic T-cell lymphoma (AITL) and if CD10 expression on neoplastic T cells, as recently reported on AITL, may contribute to the diagnosis.
  • In all, 11 lymph nodes and six peripheral blood samples from 12 patients with AITL were studied using four-colour flow cytometry associated to histological, cytological and molecular data.
  • Interestingly, all blood smears showed atypical lymphoid cells and a fraction of T cells expressed CD10 with a mean percentage of 18.75% (range 5.00-47.00%), regardless of lymphocytosis level and of rate of CD10 T cells in corresponding lymph node.
  • In contrast, in all control samples (100), none CD10-positive T cell was identified.
  • Therefore, they ought to be explored in further studies when aggressive lymphoma, in particular with lymphopenia and circulating atypical cells, is suspected.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Neoplastic Cells, Circulating / immunology. Neoplastic Cells, Circulating / pathology. Neprilysin / biosynthesis. T-Lymphocytes / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Gene Rearrangement. Genes, T-Cell Receptor gamma / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341050.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


14. Jayarajan J, Azad A: A rare cause of bilateral parotid enlargement: angioimmunoblastic T-cell lymphoma. ANZ J Surg; 2009 Oct;79(10):769
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of bilateral parotid enlargement: angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Immunoblastic / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19878191.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


15. Laforga JB, Gasent JM, Vaquero M: Potential misdiagnosis of angioimmunoblastic T-cell lymphoma with Hodgkin's lymphoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):840-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential misdiagnosis of angioimmunoblastic T-cell lymphoma with Hodgkin's lymphoma: a case report.
  • BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive neoplasm.
  • We investigated the potential utility of touch imprints evaluated in conjunction with the histology of lymph nodes in the diagnosis of AITL.
  • CASE A 58-year-old man presented with generalized lymphadenopathy, splenomegaly, and autoimmune phenomena, which complicated the diagnosis.
  • Touch imprints were obtained from the lymph node biopsy, which were valuable in making the correct diagnosis.
  • CONCLUSION: We draw attention to this neoplastic diagnosis and correlate the cytomorphologic and immunohistochemical findings with the adequate clinical setting in order to avoid misdiagnosis, primarily with Hodgkin's lymphoma and reactive hyperplasia.
  • Touch imprints are useful in the diagnosis of AITL if the broad population of proliferating cells is distinguished.
  • However, some cases display binucleated or mononucleated cells with prominent nucleoli and many eosinophils, which may induce a potential misdiagnosis with Hodgkin's lymphoma.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053552.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jaffe ES: Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program; 2006;:317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathobiology of peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTLs) are uncommon, accounting for fewer than 10% of all non-Hodgkin lymphomas.
  • Success in therapy of the PTLs has lagged behind that of aggressive B-cell lymphomas, and most PTLs have a poor prognosis.
  • In the WHO classification, clinical features, in conjunction with morphological and immunophenotypic criteria, are relied on to define most disease entities.
  • Functionally, T-cell lymphomas are related to the two major arms of the immune system, the innate and adaptive immune systems.
  • The lymphomas derived from these cells often involve cutaneous and mucosal sites.
  • The expression of cytotoxic molecules in these lymphomas may predispose to apoptosis by tumor cells and normal bystander cells.
  • Hepatosplenic T-cell lymphoma is a systemic disease derived from functionally immature innate effector cells, most often of gammadelta T-cell origin.
  • In contrast, most nodal T-cell lymphomas belong to the adaptive immune system.
  • Angioimmunoblastic T-cell lymphoma (AILT) is mostly likely derived from follicular helper T-cells (T(FH)), a finding that explains many of its pathological and clinical features.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124078.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


17. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS: Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2007 Apr;48(4):716-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
  • The objective of this retrospective study was to investigate clinical features and treatment outcomes in patients with angioimmunoblastic T-cell lymphoma (AITL), data of which were collected over a 15-year period.
  • At diagnosis, 27 patients (41.5%) presented with malignant pleural effusion, and 22 patients (33.8%) had skin involvement.
  • [MeSH-major] Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / pharmacology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Apr;48(4):645-6 [17454617.001]
  • (PMID = 17454629.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


18. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P, Groupe d'Etude des Lymphomes de l'Adulte: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood; 2008 May 1;111(9):4463-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
  • To evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials.
  • In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival.
  • In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Chemokine CXCL13 / analysis. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunoblastic Lymphadenopathy. Middle Aged. Neprilysin / analysis. Prednisone / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Analysis. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):218-24 [18182664.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):309-14 [10917533.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] Hematol J. 2001;2(6):393-5 [11920279.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Cancer. 1978 Feb;41(2):578-606 [630540.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):318-21 [6861074.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):208-12 [3802012.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1625-9 [2924270.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] Leukemia. 1991 Oct;5(10):892-5 [1961023.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1993 Jul 1;82(1):241-6 [8391875.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2354-5 [8822958.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):193-8 [9143398.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):601-3 [9261530.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Int J Hematol. 1998 Apr;67(3):319-29 [9650454.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):545-52 [10048427.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):853-65 [16261173.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1110-1 [16861359.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1077-88 [17592275.001]
  • [Cites] Medicine (Baltimore). 2007 Sep;86(5):282-92 [17873758.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 18292286.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2343588
  • [Investigator] Abdalsamad I; Dagger MF; Allard C; Angonin R; d'Anjou J; Audhuy B; Audouin J; Auzanneau G; Baglin AC; Bacilli C; Bastion Y; Baumelou E; Bensimon P; Berger F; Biron P; Blaise AM; Blanc M; Boman-Ferrand F; Boehn A; Boniver J; Bordes M; Bordessoule D; Bosly A; Bosq J; Bouabdallah R; Boucheron S; Bouvier J; Brice P; Brière J; Brousse N; Brousset P; Bryon PA; Caillot D; Carbillet JP; Casasnovas RO; Caulet T; Cazals D; Charlotte F; Charvillat L; Chesneau AM; Christian B; Coiffier B; Conroy T; Cordier JF; Cordonnier C; Clauvel JP; Deconinck E; Delage M; Delannoy A; Delmer A; Delos M; Delsol G; Devidas A; Diebold J; Diviné M; Dombret H; Doyen C; Duplay H; Dupriez B; Duval C; Eisenmann JC; Elbaz D; Emberger JM; Epardeau B; Fabiani B; Felman P; Fermand JP; Fermé C; Ferrand A; Ffrench M; Fievez M; Fillet G; Fonck Y; Froment N; Gabarre J; Galian P; Gasser O; Gaulard P; Gisselbrecht C; Gosselin B; Goutier C; Guy H; Guyotat D; Haioun C; Hamels J; Herbrecht R; Hopfner O; Horschowski N; Huguet F; Jacomy P; Jaubert J; Jeandel R; Kerneis Y; Knopf JP; Kuentz M; Labouyrie E; Lancien B; Laurent G; Lavergne A; Lavignac C; Leblond V; Lecomte-Houke M; Léderlin P; Lejeune F; Leger-Ravet MB; Loire R; Marcellin R; Marolleau JP; Marit G; Martin C; Marty-Double C; De Mascarel A; Méhaut S; Merlio JP; Merignargues C; Micléa JM; Michaux JL; Molina T; Monconduit M; Morel P; Morvan F; Mosnier JF; Nédellec G; Netter-Pinon C; Noel H; Nouvel C; Patey M; Peaud PY; Perie G; Peuchmaur M; Petrella T; Pignon B; Platini C; Pluot M; Pollet JP; Pujade-Lauraine E; Raphael M; Raymond-Gelle MC; Reiffers J; Reyes F; Rochet M; Rossi JF; Roucayrol AM; Rozenbaum A; Salles G; Schill H; Sebban C; Simon M; Solal-Céligny P; Straub P; Suc E; Sutton L; Symann M; Tertian G; Thiebaut S; Thyss A; Tilly H; Travade P; Trillet V; Vernant JP; Wendum D; Xerri L
  •  go-up   go-down


19. Kojima M, Motoori T, Matsuda H, Iijima M, Masawa N, Nakamura S: Atypical lymphoplasmacytic and immunoblastic proliferation from systemic lupus erythematosus. A case report. Pathol Res Pract; 2005;201(7):531-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lymphoplasmacytic and immunoblastic proliferation from systemic lupus erythematosus. A case report.
  • A case of atypical lymphoplasmacytic and immunoblastic proliferation (ALPIBP) in the lymph nodes associated with well-documented systemic lupus erythematosus (SLE) is presented.
  • A 30-year-old Japanese female with an 18-year history of SLE presented with right neck lymphadenopathy of 3 months duration.
  • Interestingly, the immunohistochemical study demonstrated large, irregularly shaped accumulations of follicular dendritic cells (FDCs) surrounding the small vessels, which is an immunohistochemical finding characteristic of angioimmunoblastic T-cell lymphoma (AILT).
  • However, the present lesion showed the following differences to AILT: (a) absence of CD3+, CD4+ and CD10+ clear cells, which are tumor cells of AILT;.
  • (c) on molecular analysis, the present case demonstrated a polyclonal pattern converse to the monoclonal T-cell receptor gamma chain gene rearrangement in most AILTs (d) absence of EBV infected lymphoid cells, which are frequently detected AILT.
  • As previously suggested, the present case indicates that a clinical correlation as well as immunohistologic and genotypic studies may be necessary to discriminate between ALPIBPs and AILT.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunoblastic Lymphadenopathy / pathology. Immunohistochemistry

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164050.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Bonzheim I, Geissinger E, Tinguely M, Roth S, Grieb T, Reimer P, Wilhelm M, Rosenwald A, Müller-Hermelink HK, Rüdiger T: Evaluation of FoxP3 expression in peripheral T-cell lymphoma. Am J Clin Pathol; 2008 Oct;130(4):613-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of FoxP3 expression in peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCLs) are biologically heterogeneous and have not been successfully correlated with specific T-cell subsets.
  • We investigated PTCL, not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AILT), and anaplastic large cell lymphoma (ALCL) cases for FoxP3 expression to determine a potential derivation from regulatory T (Treg) cells.
  • One PTCL-NOS case strongly expressed FoxP3 in the neoplastic T cells and showed unusual histomorphologic features with a dense infiltration of the lymph node by immunoblastic T cells and almost no reactive background infiltrate.
  • The patient died shortly after diagnosis, suggesting that biologic properties of Treg cells may have contributed to the rapidly fatal clinical course.
  • All remaining PTCL-NOS and AILT cases showed FoxP3 positivity only in the reactive infiltrate.
  • FoxP3+ PTCL-NOS presumably derived from bona fide Treg cells occurs but seems rare in the Western population.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocyte Subsets / metabolism. T-Lymphocytes, Regulatory / metabolism

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794055.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


21. Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ: Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol; 2007 Jul;138(1):44-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.
  • The clinical and histological presentations of angioimmunoblastic T-cell lymphoma (AITL) often mimic an infectious process.
  • High EBV load was also significantly associated with B-cell monoclonality.
  • Our results demonstrate an association between EBV and HHV6B infection and the histological progression of AITL, suggesting that these viruses may play a role in the pathogenesis of this lymphoma.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Infectious Mononucleosis / complications. Lymphoma, Large-Cell, Immunoblastic / virology. Roseolovirus Infections / complications. Tumor Virus Infections / complications
  • [MeSH-minor] Antigens, CD20 / analysis. Antigens, CD79 / analysis. Chi-Square Distribution. Disease Progression. Genes, Viral. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. Viral Load

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


22. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D: Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol; 2008 Jun 7;14(21):3374-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver-related autoantibodies are crucial for the correct diagnosis and classification of autoimmune liver diseases (AiLD), namely autoimmune hepatitis types 1 and 2 (AIH-1 and 2), primary biliary cirrhosis (PBC), and the sclerosing cholangitis variants in adults and children.
  • AIH-2 is specified by antibody to liver kidney microsomal antigen type-1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1).
  • SMA, ANA and anti-LKM antibodies can be present in de-novo AIH following liver transplantation.
  • PBC is specified by antimitochondrial antibodies (AMA) reacting with enzymes of the 2-oxo-acid dehydrogenase complexes (chiefly pyruvate dehydrogenase complex E2 subunit) and disease-specific ANA mainly reacting with nuclear pore gp210 and nuclear body sp100.
  • Sclerosing cholangitis presents as at least two variants, first the classical primary sclerosing cholangitis (PSC) mostly affecting adult men wherein the only (and non-specific) reactivity is an atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA), also termed perinuclear anti-neutrophil nuclear antibodies (p-ANNA) and second the childhood disease called autoimmune sclerosing cholangitis (ASC) with serological features resembling those of type 1 AIH.
  • [MeSH-major] Autoantibodies / blood. Autoantigens / immunology. Cholangitis, Sclerosing / diagnosis. Hepatitis, Autoimmune / diagnosis. Liver Cirrhosis, Biliary / diagnosis. Serologic Tests

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1969 May;4(5):511-25 [5787343.001]
  • [Cites] Immunology. 1969 Aug;17(2):281-93 [5804537.001]
  • [Cites] Am J Pathol. 1973 Sep;72(3):473-88 [4125700.001]
  • [Cites] Clin Exp Immunol. 1973 Nov;15(3):331-44 [4587503.001]
  • [Cites] Br Med J. 1974 Apr 13;2(5910):80-4 [4596402.001]
  • [Cites] Immunology. 1974 Mar;26(3):589-601 [4604207.001]
  • [Cites] Clin Exp Immunol. 1976 May;24(2):266-72 [945140.001]
  • [Cites] J Clin Pathol. 1976 May;29(5):403-10 [777046.001]
  • [Cites] Clin Exp Immunol. 1979 Dec;38(3):621-8 [93995.001]
  • [Cites] Clin Exp Immunol. 1983 Oct;54(1):232-8 [6352105.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):347-54 [6199139.001]
  • [Cites] Lancet. 1984 Oct 27;2(8409):954-6 [6149344.001]
  • [Cites] Lancet. 1985 Feb 23;1(8426):425-9 [2857806.001]
  • [Cites] Lancet. 1987 Feb 7;1(8528):292-4 [2880112.001]
  • [Cites] J Immunol. 1987 May 15;138(10):3525-31 [3571977.001]
  • [Cites] Gastroenterol Clin Biol. 1987 Aug-Sep;11(8-9):614 [3653625.001]
  • [Cites] Hepatology. 1987 Nov-Dec;7(6):1333-9 [3679093.001]
  • [Cites] Liver. 1987 Dec;7(6):307-15 [3437792.001]
  • [Cites] Lancet. 1988 May 14;1(8594):1067-70 [2896910.001]
  • [Cites] J Exp Med. 1988 Aug 1;168(2):801-6 [2842431.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):8256-60 [3186722.001]
  • [Cites] Hepatology. 2001 Mar;33(3):591-6 [11230739.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):366-72 [11322196.001]
  • [Cites] Liver. 2001 Aug;21(4):225-32 [11454184.001]
  • [Cites] Hepatology. 2001 Sep;34(3):494-501 [11526534.001]
  • [Cites] Clin Exp Immunol. 2001 Oct;126(1):37-46 [11678897.001]
  • [Cites] Liver Int. 2006 Aug;26(6):633-5 [16842317.001]
  • [Cites] Clin Chim Acta. 2006 Nov;373(1-2):183-4; author reply 185 [16714006.001]
  • [Cites] Dig Liver Dis. 2006 Oct;38(10):781-2; author reply 782-3 [16870516.001]
  • [Cites] Hepatology. 2007 Jan;45(1):118-27 [17187436.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):107-8 [17213359.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2731-6 [17227520.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Mar;22(3):454-5 [17295788.001]
  • [Cites] Hepatology. 2007 Mar;45(3):659-65 [17326160.001]
  • [Cites] PLoS Biol. 2007 Jan;5(1):e4 [17194211.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Jul;77(1):155-6 [17118481.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1131-2 [17489791.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):129-39 [17520513.001]
  • [Cites] Lancet. 1965 Oct 30;2(7418):878-9 [4158243.001]
  • [Cites] Gastroenterology. 1966 Oct;51(4):499-505 [5332194.001]
  • [Cites] J Exp Med. 1967 Aug 1;126(2):277-90 [4165742.001]
  • [Cites] Br J Exp Pathol. 1969 Apr;50(2):200-8 [5772074.001]
  • [Cites] J Autoimmun. 2004 Jun;22(4):353-62 [15120760.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):239-50 [16143941.001]
  • [Cites] Semin Liver Dis. 2005 Aug;25(3):298-310 [16143945.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1261-73 [16177252.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):280-4 [16505279.001]
  • [Cites] Hepatology. 2006 May;43(5):1135-44 [16628641.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):140-51 [17520514.001]
  • [Cites] Semin Liver Dis. 2007 May;27(2):161-72 [17520516.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1583; author reply 1583-4 [17538935.001]
  • [Cites] J Clin Immunol. 2007 Jul;27(4):378-87 [17514501.001]
  • [Cites] J Clin Lab Anal. 2007;21(4):227-31 [17621358.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:519-30 [17785341.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1226-31 [17919234.001]
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1662-6 [3192182.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):1066-72 [2466049.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1967-73 [2347920.001]
  • [Cites] Hepatology. 1990 Jul;12(1):127-32 [2373473.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1290-5 [1397887.001]
  • [Cites] Hepatology. 1992 Oct;16(4):892-8 [1398495.001]
  • [Cites] Hepatology. 1993 Mar;17(3):411-7 [8444414.001]
  • [Cites] J Immunol Methods. 1993 Feb 26;159(1-2):1-16 [8445241.001]
  • [Cites] Clin Exp Immunol. 1993 May;92(2):308-16 [7683589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9 [12832623.001]
  • [Cites] J Hepatol. 2003 Nov;39(5):860-3 [14568272.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1250-7 [14578864.001]
  • [Cites] Clin Liver Dis. 2003 Nov;7(4):759-77, vi [14594130.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1476-9 [14598264.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):31-9 [14672611.001]
  • [Cites] Dig Liver Dis. 2003 Nov;35(11):801-5 [14674671.001]
  • [Cites] J Rheumatol. 2003 Nov;30(11):2374-81 [14677180.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):682-3; author reply 683-4 [14981048.001]
  • [Cites] Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):83-92 [15000871.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):763-4; author reply 765 [15089915.001]
  • [Cites] Hepatology. 1997 Oct;26(4):1054-66 [9328334.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):324-8 [9453493.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):409-13 [9482295.001]
  • [Cites] Gut. 1998 May;42(5):721-6 [9659171.001]
  • [Cites] Hepatology. 1998 Aug;28(2):332-40 [9695994.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):643-9 [10029623.001]
  • [Cites] Ann Clin Biochem. 1999 Mar;36 ( Pt 2):189-95 [10370735.001]
  • [Cites] Experientia. 1954 Jun 15;10(6):252-3 [13183062.001]
  • [Cites] Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):789-94 [13204357.001]
  • [Cites] Lancet. 1956 Dec 29;271(6957):1323-6 [13386250.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1436-42 [17657817.001]
  • [Cites] Autoimmunity. 2008 Feb;41(1):105-10 [18176872.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):71-8 [9089912.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):79-90 [9089913.001]
  • [Cites] Hepatology. 1997 May;25(5):1090-5 [9141422.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1396-402 [9210629.001]
  • [Cites] Hepatology. 1997 Sep;26(3):567-72 [9303484.001]
  • [Cites] Hepatology. 2008 Mar;47(3):1096-7; author reply 1097 [18306217.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1948 Jan 21;23(2):25-8 [18921142.001]
  • [Cites] Hepatology. 1993 Jul;18(1):1-9 [8325600.001]
  • [Cites] J Hepatol. 1993 Aug;19(1):55-63 [8301043.001]
  • [Cites] J Clin Immunol. 1994 Jan;14(1):14-9 [8132733.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):94-9 [8033426.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1159-66 [7698584.001]
  • [Cites] Biochem Mol Biol Int. 1995 Mar;35(3):473-85 [7773184.001]
  • [Cites] Gut. 1995 May;36(5):749-54 [7797126.001]
  • [Cites] Gut. 1995 Sep;37(3):406-12 [7590439.001]
  • [Cites] J Immunol Methods. 1995 Dec 1;187(2):259-64 [7499885.001]
  • [Cites] Hepatology. 1996 Jul;24(1):97-103 [8707289.001]
  • [Cites] Dig Dis Sci. 1996 Sep;41(9):1733-40 [8794787.001]
  • [Cites] Hepatology. 1996 Nov;24(5):1068-73 [8903377.001]
  • [Cites] Hepatology. 1997 Jan;25(1):6-11 [8985257.001]
  • [Cites] Hepatology. 1997 Mar;25(3):541-7 [9049195.001]
  • [Cites] Semin Liver Dis. 1997 Feb;17(1):61-9 [9089911.001]
  • [Cites] J Hepatol. 1999 Oct;31(4):635-40 [10551386.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Am J Gastroenterol. 2001 Dec;96(12):3447-8 [11774973.001]
  • [Cites] J Hepatol. 2002 Jan;36(1):14-21 [11804659.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):68-74 [11824974.001]
  • [Cites] Hepatology. 2002 Mar;35(3):658-64 [11870381.001]
  • [Cites] J Clin Lab Anal. 2002;16(4):194-201 [12112392.001]
  • [Cites] Gut. 2002 Aug;51(2):259-64 [12117891.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):906-9 [12461054.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1481-9 [12538711.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):241-3 [12591035.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):431-7 [12591064.001]
  • [Cites] Clin Chem. 2003 Apr;49(4):634-43 [12651817.001]
  • [Cites] J Autoimmun. 2003 May;20(3):247-54 [12753810.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):475-83 [12765472.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):485-92 [12765473.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):515-9 [12765477.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):545-50 [12765481.001]
  • [Cites] Arthritis Res Ther. 2003;5(4):192-201 [12823850.001]
  • [Cites] N Engl J Med. 1958 Jan 23;258(4):185-8 [13493762.001]
  • [Cites] Proc Soc Exp Biol Med. 1957 Dec;96(3):575-9 [13505796.001]
  • [Cites] Lancet. 1959 Jan 10;1(7063):65-9 [13621639.001]
  • [Cites] Cancer Res. 1955 Oct;15(9):598-602 [13261081.001]
  • [Cites] J Clin Invest. 1959 Nov;38:2059-72 [14402750.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1116-22 [15625657.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):508-10 [15712071.001]
  • [Cites] Hepatology. 2005 Mar;41(3):609-16 [15726652.001]
  • [Cites] Hepatology. 2005 Aug;42(2):458-65 [16025495.001]
  • [Cites] Scand J Gastroenterol. 2004 Apr;39(4):405-6; author reply 407 [15125479.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1505; author reply 1505-6 [15156495.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):31-7 [15246204.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):677-83 [15464251.001]
  • [Cites] Scand J Gastroenterol. 2004 Oct;39(10):981-7 [15513338.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] Lancet. 2000 Apr 29;355(9214):1510-5 [10801173.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):310-22 [10930366.001]
  • [Cites] Dig Liver Dis. 2000 Jun-Jul;32(5):440-6 [11030191.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3238-41 [11095348.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):239-49 [11208733.001]
  • [Cites] Hepatology. 2001 Mar;33(3):544-53 [11230733.001]
  • (PMID = 18528935.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Reagent Kits, Diagnostic
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC2716592
  •  go-up   go-down


23. Lachenal F: [Angioimmunoblastic T-cell lymphoma]. Presse Med; 2007 Nov;36(11 Pt 2):1655-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma].
  • [Transliterated title] Lymphomes T angio-immunoblastiques.
  • Angioimmunoblastic T-cell lymphoma most often affects the elderly.
  • Patients present with generalized lymphadenopathy and systemic symptoms; half also have hepatomegaly, splenomegaly and a rash.
  • Lymph node biopsy is needed to confirm this diagnosis.
  • Genetic analysis that reveals a monoclonal T-cell population is also relevant.
  • Autologous stem cell transplantation is proposed to the youngest.
  • [MeSH-major] Immunoblastic Lymphadenopathy. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587541.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


24. Kang HY, Hwang JH, Park YS, Bang SM, Lee JS, Chung JH, Kim H: Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease. Dig Dis Sci; 2007 Oct;52(10):2743-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease.
  • [MeSH-major] Crohn Disease / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Biopsy, Needle. Dexamethasone / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use. Middle Aged. Severity of Illness Index. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):545-52 [10048427.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer. 1988 Jun 1;61(11):2244-50 [3365652.001]
  • [Cites] Pathol Res Pract. 2003;199(8):539-45 [14533938.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1259-67 [1739925.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Jan;21(1):80-4 [15687889.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):950-4 [12143251.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):343-7 [12612513.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • (PMID = 17394065.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004.
  • Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%).
  • After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • Patients who are transplanted in a refractory disease state do not benefit from this procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Registries. Severity of Illness Index. Spain. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


26. Rüdiger T, Geissinger E, Müller-Hermelink HK: 'Normal counterparts' of nodal peripheral T-cell lymphoma. Hematol Oncol; 2006 Dec;24(4):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Normal counterparts' of nodal peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCL) have been difficult to classify.
  • A homogeneous principle of classification is still lacking, partly because lymph node compartments containing functionally distinct T-cell subsets have not been identified.
  • A correlation to differentiated T-cell subsets, as CD4(+) or CD8(+) cells as well as cytotoxic populations has not revealed clinically meaningful entities.
  • Immunohistological analysis of PTCL showed an effector or effector-memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(-)) for both angioimmunoblastic T-cell lymphoma (AILT) and anaplastic large cell lymphoma (ALCL), but different cytotoxic and activation markers expressed by these tumours.
  • A subset of CD4(+) PTCL-not otherwise specified (PTCL-NOS) may correspond to a central memory cell phenotype (CD45RA(-)/CD45R0(+)/CD27(+)).
  • A comparison between the lymphomas and their normal counterparts may contribute to the understanding of the underlying transformation mechanisms.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / immunology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Differentiation / immunology. Immunologic Memory. Lymphoma, T-Cell, Peripheral / immunology
  • [MeSH-minor] Cell Transformation, Neoplastic / immunology. Gene Expression Regulation, Leukemic / immunology. Humans. Lymph Nodes / immunology. Lymph Nodes / pathology. Lymphocyte Activation / immunology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783841.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte
  • [Number-of-references] 73
  •  go-up   go-down


27. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A: Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia; 2006 Feb;20(2):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma.
  • Among peripheral T-cell lymphomas (PTCL), the heterogeneous category of unspecified PTCL represents the most common subtype.
  • Nevertheless, recurrent chromosomal translocations are unknown in this aggressive type of lymphoma.
  • ITK-SYK transcripts were detected in five of 30 (17%) unspecified PTCL, but not in cases of angioimmunoblastic T-cell lymphoma (n=9) and anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma (n=7).
  • [MeSH-major] Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 9 / genetics. Intracellular Signaling Peptides and Proteins / genetics. Lymphoma, Non-Hodgkin / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2006 Feb;20(2):208-9 [16307012.001]
  • (PMID = 16341044.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / emt protein-tyrosine kinase
  •  go-up   go-down


28. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, Novitzky N, Goldstone AH, Sureda A, Schmitz N: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol; 2009 Aug 20;27(24):3951-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
  • PURPOSE: To analyze the long-term outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS) in patients with angioimmunoblastic T-cell lymphoma (AITL) treated with allogeneic stem-cell transplantation (alloSCT).
  • Median age was 48 years (range, 23 to 68 years), 34 patients had received > or = two lines of chemotherapy before alloSCT, and 11 patients had experienced treatment failure with a prior autologous stem-cell transplantation.
  • Twenty-seven patients were allografted in chemotherapy-sensitive disease, and 18 were allografted in refractory disease.
  • RR was estimated as 16% and 20% at 2 and 3 years, respectively, and was lower in patients developing chronic graft-versus-host disease (cGVHD).
  • Both the lower RR after transplantation as well as the decreased RR in patients developing cGVHD after the alloSCT suggests the existence of a clinically relevant graft-versus-lymphoma effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Aged. Female. Graft vs Host Disease / epidemiology. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620487.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Chang CJ, Cheng JH, Lin MS, Dai YC, Hsiue TR: Eosinophilic pleural effusion as the first presentation of angioimmunoblastic T cell lymphoma. J Formos Med Assoc; 2007 Feb;106(2):156-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic pleural effusion as the first presentation of angioimmunoblastic T cell lymphoma.
  • Eosinophilic pleural effusion (EPE), defined as pleural effusion that contains at least 10% eosinophils among the leukocytes, can be a manifestation of a great variety of diseases.
  • However, eosinophilia is a relatively rare finding in malignant pleural effusions, and it has been used as an indicator of good prognosis.
  • In clinical experience, very few cases of malignant lymphomas accompanied by EPE have been reported.
  • Pleural biopsy could not yield a definite diagnosis initially.
  • Six months later, bilateral neck, axillary and inguinal lymphadenopathy developed, and lymph node biopsy confirmed the diagnosis of angioimmunoblastic T cell lymphoma, with positive CD10 expression.
  • Therefore, we retrospectively carried out CD10 staining of the sample obtained from pleural biopsy and the positive result confirmed that the etiology of EPE was due to malignant T cell lymphoma.

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339160.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


30. Pujol RM, Gallardo F, Servitje O, Martí RM, Bordes R, García-Muret MP, Estrach MT, Nomdedeu JF: Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: a clinicopathologic study of four cases. J Dermatol; 2005 Jul;32(7):541-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: a clinicopathologic study of four cases.
  • Epithelioid granuloma formation has rarely been observed in specific cutaneous lesions from T-cell lymphomas other than those of mycosis fungoides/Sézary syndrome (MF/SS).
  • Three patients diagnosed with nodal and/or extranodal (tonsillar) non-Hodgkin's peripheral T-cell lymphoma (PTCL) and one patient with angioimmunoblastic T-cell lymphoma (AILD), developed specific cutaneous involvement showing prominent epithelioid cell and/or granulomatous inflammation.
  • Sarcoid-like granulomas were observed in two patients (one of them presented a granuloma annulare-like pattern in early lesions), granulomatous panniculitis was noted in one patient and in one patient with AILD, masses of epithelioid cells were noted.
  • The clinicopathological features of cutaneous involvement by PTCL showing a florid epithelioid and/or granulomatous cell reaction are reviewed.
  • [MeSH-major] Epithelioid Cells / pathology. Granuloma / complications. Lymphoma, T-Cell, Peripheral / complications. Skin Diseases / complications


31. Qin Y, Shi YK, He XH, Yang JL, Zhang CG, Zhou SY, Liu XF, Liu P, Yang S, Zhou LQ, Han XH, Yao JR: [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2010 Jun;32(6):448-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
  • OBJECTIVE: To retrospectively analyze the clinical features and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).
  • All of the patients received CHOP-like regimens as initial chemotherapy, including 4 once treated with radiotherapy and 1 with high dose therapy followed by autologous stem cell transplantation (HDT-ASCT) as upfront consolidation therapy.
  • B-cell, T-cell and NK-cell subgroup proportions in the peripheral blood were tested by flow cytometry in 6 patients.
  • With the median follow-up of 26 months, the overall 2-year survival and disease free survival (DFS) rates were 62.2% and 44.4%, respectively.
  • In the univariate analysis, only age > 30 years and primary refractory disease adversely affected overall survival (OS); age > 30 years, advanced stage, B symptoms and splenomegaly adversely affected DFS.
  • Flow cytometry of peripheral blood lymphocytes showed that 5 of the 6 tested cases had decreasing proportion of CD3(+)CD4(+) T cells, B cells and NK cells but elevated CD3(+)CD8(+) T cells.
  • Two heavily treated patients achieved partial and complete response by thalidomide therapy, with a progression free survival (PFS) of 2 and 6+ months, respectively.
  • Peripheral blood lymphocytes test indicates that AITL patients suffered from both natural and acquired immune defects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Pneumonia / etiology. Prednisone / therapeutic use. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Thalidomide / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819488.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.
  • B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function.
  • In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease.
  • We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms.
  • In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.
  • These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


33. Tsochatzis E, Vassilopoulos D, Deutsch M, Filiotou A, Tasidou A, Archimandritis AJ: Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol; 2005 Dec;11(6):326-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of non-Hodgkin lymphoma with systemic manifestations, including fever, lymphadenopathy, rash, and rarely arthritis.
  • AITL-associated arthritis is an uncommon manifestation of angioimmunoblastic lymphoma that can mimic RA, especially when the typical systemic features of lymphoma are absent.
  • This type of arthritis should be included in the differential diagnosis of patients presenting with an inflammatory polyarthritis.
  • [MeSH-major] Arthritis / etiology. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neck

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371804.001).
  • [ISSN] 1076-1608
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Shinohara A, Asai T, Izutsu K, Ota Y, Takeuchi K, Hangaishi A, Kanda Y, Chiba S, Motokura T, Kurokawa M: Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2007 Feb;48(2):418-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Herpesvirus 4, Human / genetics. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell, Peripheral / complications. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. DNA, Viral / genetics. Humans. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / therapy. Male. Middle Aged. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / virology. Remission Induction. Rituximab


35. Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C: Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology; 2007 Apr;50(5):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Protein kinase C (PKC) beta is an important regulator of lymphoid survival and its expression has been shown to be altered in lymphomas.
  • The aim was to determine the expression of PKC beta(2) in various subtypes of lymphoproliferative diseases by immunohistochemistry.
  • METHODS AND RESULTS: One hundred and forty archival samples representing various subtypes of lymphoproliferative diseases were analysed.
  • Certain subtypes, such as mantle cell, lymphocytic or follicular lymphoma, were found to express PKC beta(2) in > 90% of the samples.
  • In follicular lymphomas, the follicular lymphomatous areas were constantly labelled, whereas residual germinal centres remained negative.
  • Most angioimmunoblastic T-cell lymphomas, lymphoblastic T-cell lymphomas and marginal zone/mucosa-associated lymphoid tissue (MALT) lymphomas were labelled with anti-PKC betaII antibody, but the pattern of expression was more heterogeneous in these subtypes.
  • A minority of diffuse large B-cell lymphomas were stained and most plasma cell malignancies were negative.
  • None of the cases of Hodgkin's disease and anaplastic large cell lymphoma expressed PKC beta(2).
  • CONCLUSIONS: PKC beta(2) expression varies significantly among lymphoproliferative diseases.
  • In our series, the highest level of expression was found in mantle cell lymphomas and chronic lymphocytic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394491.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


36. Renner R, Kauer F, Treudler R, Niederwieser D, Simon JC: Eosinophilic cellulitis (Wells' syndrome) in association with angioimmunoblastic lymphadenopathy. Acta Derm Venereol; 2007;87(6):525-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic cellulitis (Wells' syndrome) in association with angioimmunoblastic lymphadenopathy.
  • Eosinophilic cellulitis (Wells' syndrome) is an uncommon inflammatory disease with clinical polymorphism.
  • It is often associated with infectious, allergic or myeloproliferative diseases; however, the exact aetiology is unknown.
  • This report describes a rare case of eosinophilic cellulitis in association with angioimmunoblastic lymphadenopathy.
  • The typical skin findings of Wells' syndrome disappeared completely following chemotherapy and autologous stem cell transplantation.
  • [MeSH-major] Cellulitis / complications. Eosinophilia / complications. Immunoblastic Lymphadenopathy / complications. Skin Diseases / complications


37. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • Little is known about long-term outcome and prognostic factors of these diseases.
  • To a large extent, the IPI score explains the differences in survival between histological subtypes of nodal mature T-cell lymphomas.
  • The IPI may therefore be used for risk stratification in clinical trials to identify patients who would benefit most from new treatment strategies, such as high-dose chemotherapy followed by stem cell or bone marrow transplantation.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Welch KD, Wen B, Goodlett DR, Yi EC, Lee H, Reilly TP, Nelson SD, Pohl LR: Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem Res Toxicol; 2005 Jun;18(6):924-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of potential susceptibility factors in drug-induced liver disease.
  • Drug-induced liver disease (DILD) causes significant morbidity and mortality and impairs new drug development.
  • As an approach to better understand the multifactorial basis of DILD, we compared the hepatic proteome of mice that are resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD), using solution-based isotope-coded affinity tag (ICAT) liquid chromatography mass spectrometry.
  • Several novel factors were identified that were more highly expressed in the livers of SJL mice, including those involved in stress response, cell proliferation and tissue regeneration, and protein modification, implicating these proteins as potential hepatoprotective factors.
  • There was also a selective loss of several mitochondrial proteins from the livers of the susceptible C57Bl/6 mice, suggesting that the loss of functional mitochondria may indeed play a role in AILD.
  • [MeSH-minor] Acetaminophen / toxicity. Affinity Labels / chemistry. Animals. Chromatography, Affinity. Disease Susceptibility / metabolism. Drug Resistance. Liver Diseases / metabolism. Liver Diseases / mortality. Male. Mass Spectrometry. Mice. Mice, Inbred C57BL. Mitochondria, Liver / drug effects. Mitochondria, Liver / metabolism. Species Specificity

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962927.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES 07033; United States / NCRR NIH HHS / RR / P51 RR 00166
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


39. Krenacs L, Schaerli P, Kis G, Bagdi E: Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood; 2006 Aug 1;108(3):1110-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. T-Lymphocytes, Helper-Inducer / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Aug 15;106(4):1501-2 [16079436.001]
  • (PMID = 16861359.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


40. Dogan A, Ngu LS, Ng SH, Cervi PL: Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia; 2005 May;19(5):873-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide.
  • [MeSH-major] Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744336.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


41. Prochazka V, Faber E, Raida L, Vondrakova J, Kucerova L, Jarosova M, Indrak K, Papajik T: Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar;153(1):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
  • BACKGROUND: Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin's lymphomas.
  • The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL).
  • Optimal first-line chemotherapy is not established and the role of high-dose therapy with autologous stem cell support is still controversial.
  • Consolidation was provided with myeloablative conditioning (BEAM 200) and autologous stem cell support.
  • Eighty-four patients with aggressive high-risk lymphoma were treated with the sequential protocol from 2000 to 2007 in our institution.
  • Here we report our experience with 18 patients with nodal PTCL (10 PTCL, NOS; 3 ALCL, ALKnegative; 2 ALCL, ALK-positive; 2 ALCL, unknown ALK status; 1 AIL).
  • After a median follow-up of 25.7 months, nine patients relapsed or progressed (6 PTCL, NOS; 2 ALCL ALK-positive; 1 ALCL ALK-negative; median 14.1 months) and four patients died (lymphoma progression).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / mortality. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365529.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


42. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • METHODS: Seventy AILT cases were identified over a period of 8 years.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


43. Drakos E, Rassidakis GZ, Tsioli P, Lai R, Jones D, Medeiros LJ: Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):132-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of WT1 gene product in non-Hodgkin lymphomas.
  • However, WT1 expression in non-Hodgkin lymphomas (NHLs) has not been studied.
  • The authors assessed for WT1 expression in six lymphoma/leukemia cell lines using Western blot methods after subcellular fractionation.
  • The B-cell NHLs analyzed were 18 diffuse large B-cell lymphomas, 13 marginal zone B-cell lymphomas, 9 small lymphocytic lymphomas, (DLBCLs), 8 follicular lymphomas, 6 mantle cell lymphomas, 5 Burkitt lymphomas, 3 lymphoplasmacytic lymphomas, and 2 B-cell lymphoblastic lymphomas.
  • The T-cell NHLs analyzed were 43 anaplastic large cell lymphomas (ALCLs), 26 peripheral T-cell lymphomas unspecified, 13 angioimmunoblastic T-cell lymphomas, 6 cutaneous ALCLs, 6 cases of mycosis fungoides, 5 extranodal NK/T-cell lymphomas of nasal type, and 4 T-cell lymphoblastic lymphomas.
  • WT1 levels were higher in cytoplasmic extracts than in nuclear extracts of the Karpas 299 and SU-DHL-1 lymphoma cell lines but were higher in nuclear extracts than in the cytoplasmic extracts of the Jurkat, HH, U-937, and K562 leukemia cell lines.
  • In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.
  • WT1 immunoreactivity was primarily cytoplasmic in all positive NHLs except T-cell lymphoblastic lymphoma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894924.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


44. Woda BA: Hypersensitivity pneumonitis: an immunopathology review. Arch Pathol Lab Med; 2008 Feb;132(2):204-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Hypersensitivity pneumonitis (HSP) is an immunologically mediated alveolar and interstitial lung disease caused by repeated inhalation of organic dusts and some occupational agents.
  • A number of unexplained features of HSP remain, namely (1) why do so few exposed individuals develop clinical HSP, (2) what triggers an acute episode after prolonged periods of previous sensitization, and (3) what leads to disease progression.
  • CONCLUSIONS: Current data suggest that individuals with a T(H)1 dominant response are likely to develop clinical disease.
  • There is also some evidence that genetic factors such as polymorphisms in the major histocompatibility complex, tumor necrosis factor alpha, and tissue inhibitor of metalloproteinase 3 are associated with the development of or resistance to the disease.
  • [MeSH-minor] Genetic Predisposition to Disease. Humans. Killer Cells, Natural / immunology. Lung / immunology. Lung / pathology. T-Lymphocyte Subsets / immunology. Th1 Cells / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251577.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


45. Todd T, Erber W: Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood. Br J Haematol; 2006 Jul;134(2):124
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764685.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


46. Braiteh F, Parikh A, McLaughlin P: A suspicion of chikungunya leading to a diagnosis of angioimmunoblastic T-cell lymphoma. Acta Oncol; 2009;48(4):624-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A suspicion of chikungunya leading to a diagnosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Alphavirus Infections / diagnosis. Chikungunya virus. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Exanthema / etiology. Fever / etiology. Fluorodeoxyglucose F18. Humans. In Situ Hybridization, Fluorescence. India. Male. Middle Aged. Polymerase Chain Reaction. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chikungunya.
  • MedlinePlus Health Information. consumer health - Chikungunya.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173091.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Inoue D, Kimura T, Shimoji S, Mori M, Nagai Y, Tabata S, Kurata M, Matsushita A, Nagai K, Maruoka H, Yamashita E, Takahashi T: [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis]. Rinsho Ketsueki; 2009 Feb;50(2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma complicated by recurrent drug-induced agranulocytosis].
  • A 73-year-old man was hospitalized with fever, erythema, generalized superficial lymphadenopathy and marked neutropenia in July 2007.
  • Hematologic examination demonstrated a white blood cell count of 1,400/microl with 0% neutrophils, and 18% abnormal lymphocytes.
  • A diagnosis of drug-induced agranulocytosis was made.
  • Although neutrophil counts immediately returned to normal levels in response to filgrastim, fever, skin rash and systemic lymphadenopathy were all persistent.
  • Based on the histologic findings, PCR, and immunohistologic analyses, he was diagnosed with angioimmunoblastic T cell lymphoma (AILT) in leukemic state.
  • The response of the lymphoma to conventional chemotherapy (CHOP and ESHAP) was poor.
  • The treatment resulted in a partial remission of AILT including disappearance of circulating lymphoma cells.
  • To our knowledge, this is the first published report of AILT complicated by drug-induced agranulocytosis.
  • [MeSH-major] Acetaminophen / adverse effects. Agranulocytosis / chemically induced. Analgesics, Non-Narcotic / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, T-Cell / etiology

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265300.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Immunosuppressive Agents; 362O9ITL9D / Acetaminophen; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


48. Tang XF, Li GD, Li YL, Liang DN, Xia T, Zhou JY, Yao YQ, Wu WQ, Wang ZG, Yang YH, Tang XB, Bai YQ, Ding Q: [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
  • OBJECTIVE: To study the value of immunomarkers CXCL13, CD10, bcl-6 in pathologic diagnosis of angioimmunoblastic T-cell lymphoma (AITL).
  • METHODS: One hundred and fifteen cases of AITL, 30 cases of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and 30 cases of reactive lymph nodes with paracortical hyperplasia (RH) encountered during the period from January, 1990 to January, 2008 were retrieved from the archival files of the Department of Pathology, West China Hospital of Sichuan University, China.
  • The morphologic features were reviewed and compared.
  • RESULTS: Regressed follicles were evident in 7.8% (9/115) of AITL cases, 6.7% (2/30) of PTCL, NOS cases and 83.3% (25/30) of RH cases, respectively.
  • A marked increase of number of arborizing venules was shown in 98.3% (113/115) of AITL cases, 63.3% (19/30) of PTCL, NOS cases and 76.7% (23/30) of RH cases, respectively.
  • In AITL, 96.5% (111/115) of cases showed CXCL13 expression, in contrast to 26.7% (8/30) of PTCL, NOS.
  • Expression of CD10 and bcl-6 were found in the neoplastic cells in 50.4% (58/115) and 78.3% (90/115) of AITL, and 3.3% (1/30) and 3.3% (1/30) of PTCL, NOS, respectively.
  • CONCLUSIONS: AITL is a type of lymphoma originated from the follicular helper T cells.
  • Detailed morphologic assessment and use of immunohistochemical markers are essential for accurate diagnosis.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-6 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Pseudolymphoma / metabolism. Pseudolymphoma / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575892.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


49. Yee SB, Bourdi M, Masson MJ, Pohl LR: Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol; 2007 May;20(5):734-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease.
  • Recent evidence suggests that a deficiency in one or more hepatoprotective regulatory mechanisms may contribute to determining susceptibility in drug-induced liver disease.
  • In the present study, we investigated the role of interleukin (IL)-13 in acetaminophen (APAP)-induced liver disease (AILD).
  • Following APAP (200 mg/kg) administration to male C57BL/6 wild-type (WT) mice, hepatotoxicity developed up to 24 h post-APAP, with a concomitant increase in serum IL-13 concentration.
  • No difference was observed in either overall APAP-protein adduct formation or liver glutathione levels between KO and WT mice following APAP administration, suggesting that the increased susceptibility of IL-13 KO mice to AILD was not due to enhanced APAP bioactivation but rather injurious downstream events.
  • In this regard, multiplex antibody arrays were used to identify potential IL-13-regulated biomarkers, including various cytokines and chemokines, as well as nitric oxide (NO), associated with AILD that were present at higher concentrations in the sera of APAP-treated IL-13 KO mice than in WT mice.
  • Subsequent inhibition studies determined interferon-gamma, NO, neutrophils, natural killer cells, and natural killer cells with T-cell receptors had pathologic roles in AILD in IL-13 KO mice.
  • Taken together, these results suggest that IL-13 is a critical hepatoprotective factor modulating the susceptibility to AILD and may provide hepatoprotection, in part, by down-regulating protoxicant factors and cells associated with the innate immune system.
  • [MeSH-major] Acetaminophen / toxicity. Analgesics, Non-Narcotic / toxicity. Drug-Induced Liver Injury / prevention & control. Interleukin-13 / blood
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Antibodies, Blocking / pharmacology. Biomarkers / blood. Disease Models, Animal. Drug Synergism. Gene Silencing. Glutathione / metabolism. Liver / drug effects. Liver / metabolism. Liver / pathology. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Neutrophils / drug effects. Neutrophils / metabolism. Neutrophils / pathology


50. Jayaraman AG, Cassarino D, Advani R, Kim YH, Tsai E, Kohler S: Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. J Cutan Pathol; 2006 Sep;33 Suppl 2:6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology.
  • Angioimmunoblastic T-cell lymphoma (AILT) is an aggressive peripheral T-cell lymphoma that is frequently accompanied by a cutaneous eruption.
  • Here, we review the previously reported histologic patterns and present a case of AILT involving the skin with a unique histologic appearance of necrotizing granulomas with abundant histiocytes and eosinophils, mimicking an infectious etiology.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Skin Diseases, Infectious / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged


51. Awaya N, Adachi A, Mori T, Kamata H, Nakahara J, Yokoyama K, Yamada T, Kizaki M, Sakamoto M, Ikeda Y, Okamoto S: Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Leuk Res; 2006 Aug;30(8):1059-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
  • Post-transplant lymphoproliferative disorder (PTLD) is a complication that can develop after either solid-organ or hematopoietic stem cell transplantation (HSCT).
  • T-cell PTLD is a rare disorder, especially following autologous HSCT.
  • Here we report a case of T-cell PTLD which occurred after autologous peripheral blood stem cell transplantation (PBSCT) for relapsed angioimmunoblastic T-cell lymphoma (AILT).
  • Our post-mortem study confirmed the marked proliferation of EBV-infected T-cells that differed from the original AILT clone and macrophages/histiocytes were observed in the marrow, liver, lymph nodes and lungs.
  • The patient's AILT remained in complete remission.
  • To the best of our knowledge, this is the first case of fulminant EBV-associated T-cell lymphoproliferative disorder (LPD) following autologous HSCT.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy. Lymphoproliferative Disorders / complications. Peripheral Blood Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330097.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


52. Khokhar FA, Payne WD, Talwalkar SS, Jorgensen JL, Bueso-Ramos CE, Medeiros LJ, Vega F: Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study. Hum Pathol; 2010 Jan;41(1):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study.
  • Angioimmunoblastic T-cell lymphoma is known to frequently involve bone marrow.
  • However, the histologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma at this site are poorly defined.
  • We assessed 27 bone marrow specimens involved by angioimmunoblastic T-cell lymphoma from 20 patients.
  • Flow cytometry immunophenotyping revealed a CD3+CD10+ T-cell population in 2 (25%) of 8 cases assessed.
  • We conclude that the recognition and classification of angioimmunoblastic T-cell lymphoma in bone marrow are made difficult by the uncommon expression of CD10 (25%), rarity of follicular dendritic cells, and lack of CXCL13 expression at this site.
  • By contrast, programed death-1 immunohistochemical staining and double labeling using antibodies specific for BCL-6 and CD3 were helpful in appreciating the follicular T-helper cell immunophenotype of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Chemokine CXCL13 / metabolism. DNA-Binding Proteins / metabolism. Female. Flow Cytometry. Humans. Immunophenotyping. Intercellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Neprilysin / metabolism. Programmed Cell Death 1 Ligand 2 Protein. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740519.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / PDCD1LG2 protein, human; 0 / Programmed Cell Death 1 Ligand 2 Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


53. Blom E, Heyning FH, Kroes WG: A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1). Cancer Genet Cytogenet; 2010 Oct 1;202(1):38-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
  • Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
  • Here, we report on a 66-year-old male with angioimmunoblastic T-cell NHL.
  • It represented an inverted duplication of the segments between 1q21 and 1qter with a neocentromere in band 1q31.
  • To our knowledge, this is the second reported case of NHL (both T-cell) with the presence of a neocentromere.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 1. Gene Duplication. Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804919.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


54. Ortonne N, Dupuis J, Plonquet A, Martin N, Copie-Bergman C, Bagot M, Delfau-Larue MH, Gaulier A, Haioun C, Wechsler J, Gaulard P: Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). Am J Surg Pathol; 2007 Jul;31(7):1068-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL).
  • Skin manifestations of angioimmunoblastic T-cell lymphoma (AITL) are frequent, sometimes as first manifestations of the disease.
  • In the absence of a specific marker for neoplastic cells, diagnosis of AITL in skin biopsies is often difficult.
  • A few CD10 lymphocytes were found in only 2 samples of the AITL group, the identification of which was hampered by the presence of a dermal CD10 cell population with dendritic features.
  • In another case, a diagnosis of cutaneous marginal zone B-cell lymphoma had been proposed.
  • In conclusion, this study shows that neoplastic AITL CXCL13 T cells localize in the skin and that accurate diagnosis of AITL lesions can be done in skin specimens using CXCL13 immunostaining on paraffin-embedded tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chemokines, CXC / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592274.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


55. Hawley RC, Cankovic M, Zarbo RJ: Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med; 2006 Nov;130(11):1707-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma.
  • Patients with angioimmunoblastic T-cell lymphoma can have profound immune dysfunction and immunodeficiency.
  • Epstein-Barr virus-driven B-cell lymphoid proliferation can occur in angioimmunoblastic T-cell lymphoma, as in other immunodeficiency states.
  • However, few cases of Epstein-Barr virus-positive B-cell lymphoma arising in patients with preexisting angioimmunoblastic T-cell lymphoma have been reported.
  • We report a case of angioimmunoblastic T-cell lymphoma in which diffuse large B-cell lymphoma developed 56 months after the diagnosis of angioimmunoblastic T-cell lymphoma.
  • The patient survived for 9 years after the initial diagnosis of angioimmunoblastic T-cell lymphoma, and molecular studies performed on multiple biopsy specimens during this period revealed the dynamic nature of clonal lymphoid expansion.
  • Epstein-Barr virus latent membrane protein 1 and Epstein-Barr virus-encoded RNA were detected in the diffuse large B-cell lymphoma, suggesting that Epstein-Barr virus may have played a role in the pathogenesis of the diffuse large B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / pathology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076535.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


56. Yoshida A, Kawano Y, Kato K, Yoshida S, Yoshikawa H, Muta T, Eto T, Gondo H, Shibuya T, Ishibashi T, Yamana T: Apoptosis in perforated cornea of a patient with graft-versus-host disease. Can J Ophthalmol; 2006 Aug;41(4):472-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis in perforated cornea of a patient with graft-versus-host disease.
  • CASE REPORT: Although ocular complications associated with graft-versus-host disease (GVHD) can include corneal dysfunction, corneal perforation is not common.
  • A 72-year-old man with the angioimmunoblastic type of malignant lymphoma developed chronic GVHD after allogeneic peripheral blood stem cell transplantation.
  • This revealed thinning of the epithelial cell layer and stroma, with cells, including lymphocytes, infiltrating to the site of the perforation.

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883364.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Khosravi Shahi P, Díaz Muñoz de la Espada VM, Encinas García S: [Angioimmunoblastic T-cell lymphoma: a case report and review of the literature]. An Med Interna; 2006 Jan;23(1):49-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma: a case report and review of the literature].
  • [Transliterated title] Linfoma T angioinmunoblástico: caso clínico y revisión de la literatura.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596737.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


58. Pro B, McLaughlin P: Angioimmunoblastic T-cell lymphoma: still a dismal prognosis with current treatment approaches. Leuk Lymphoma; 2007 Apr;48(4):645-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: still a dismal prognosis with current treatment approaches.
  • [MeSH-major] Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Neovascularization, Pathologic
  • [MeSH-minor] Anthracyclines / pharmacology. Disease-Free Survival. Humans. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • (PMID = 17454617.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


59. Warnke RA, Jones D, Hsi ED: Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol; 2007 Apr;127(4):511-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics.
  • Given their relative rarity, one of the primary diagnostic difficulties in nodal T-cell lymphomas is recognizing their range of histologic patterns.
  • This is complicated by the fact that most mature T-cell lymphomas retain some functional characteristics of nonneoplastic T cells, ie, the capacity to secrete cytokines and costimulate immune cell growth, and, thus, are associated with obscuring nonneoplastic immune cells.
  • Sessions 2 and 3 of the Society for Hematopathology/European Association for Haematopathology Workshop focused on these issues and conditions that may simulate T-cell lymphomas.
  • We summarize salient features of presented cases, including the varied patterns seen in angioimmunoblastic T-cell lymphoma (AITL) and other more poorly characterized morphologic and functional nodal T-cell lymphoma subsets.
  • Many cases illustrated the difficulties distinguishing AITL from peripheral T-cell lymphoma, unspecified, when the neoplasms manifest only some AITL features.
  • The usefulness of separately classifying T-cell lymphomas that demonstrate follicular, perifollicular, or T-zone patterns of infiltration; significance of immunophenotypically distinct subsets that express cytotoxic markers or have features of central memory T cells; diagnostic difficulties posed by B-cell proliferations that accompany T-cell lymphomas; and T-cell lymphoma mimics related to genetic disorders, immune dysregulation, and drug reactions are also discussed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunophenotyping

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369127.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Luzzatto F, Pruneri G, Benini E, Manzotti M, Laszlo D, Martinelli G, Viale G: Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. Histopathology; 2005 Apr;46(4):464-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement.
  • [MeSH-major] B-Lymphocytes / pathology. Gene Rearrangement. Germinal Center / pathology. Immunoblastic Lymphadenopathy / pathology. Immunoglobulin Heavy Chains / genetics. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810960.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Heavy Chains; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


61. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC, International Peripheral T-Cell Lymphoma Project: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood; 2010 Feb 4;115(5):1026-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
  • Peripheral T-cell lymphoma (PTCL) is often challenging to diagnose and classify.
  • Gene expression profiling was performed on 144 cases of PTCL and natural killer cell lymphoma and robust molecular classifiers were constructed for angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma.
  • Many of the pathologic features and substantial components of the molecular signature of AITL are contributed by the follicular dendritic cells, B-cell, and other stromal components.
  • The expression of Th17-associated molecules in ALK(+) ALCL was noted and may represent aberrant activation of Th17-cell differentiation by abnormal cytokine secretion.
  • Adult T-cell leukemia/lymphoma has a homogeneous molecular signature demonstrating high expression of human T-lymphotropic virus type 1-induced genes.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2006-10 [14764663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5154-7 [15100251.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):605-13 [15289861.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Nouv Rev Fr Hematol. 1990;32(1):39-41 [2140884.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Feb 1;89(3):948-56 [9028326.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1284-93 [16160469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Jul 1;108(1):218-27 [16527888.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):175-80 [16783841.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):817-28 [17202343.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):613-24 [17465721.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1382-7 [17693651.001]
  • [Cites] BMC Genomics. 2007;8:230 [17623099.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):151-60 [18071945.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):48-57 [19011627.001]
  • [Cites] Nat Rev Immunol. 2009 Jan;9(1):39-46 [19079134.001]
  • [Cites] Arthritis Rheum. 2009 Mar;60(3):750-9 [19248112.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Curr Hematol Malig Rep. 2006 Jun;1(2):129-36 [20425343.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):525-33 [11169934.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4333-43 [11970975.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16831-6 [11877449.001]
  • [Cites] J Mol Diagn. 2002 Aug;4(3):137-43 [12169674.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 2004 Jan 1;103(1):236-41 [12958063.001]
  • [CommentIn] Blood. 2010 Feb 4;115(5):919-20 [20133472.001]
  • (PMID = 19965671.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE19069
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / CA36727; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / P30 CA036727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2817630
  •  go-up   go-down


62. de Leval L, Gaulard P: Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program; 2008;:272-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathobiology and molecular profiling of peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare diseases, usually manifesting clinical aggressiveness.
  • Angioimmunoblastic T-cell lymphoma (AITL) comprises CD4+ CXCL13+ neoplastic cells displaying overlapping immunophenotypical and molecular features with normal follicular helper T cells.
  • This derivation might account for the presence of a prominent non-neoplastic component in AITL tissues and the clinical manifestations of the disease reflective of an immunological dysfunction.
  • ALK+ anaplastic large cell lymphoma (ALCL), defined by ALK gene translocation with various gene partners, is composed of CD30+ ALK+ cells with a cytotoxic phenotype and usually carries a good prognosis.
  • ALK- ALCL, now considered as a distinct disease entity, is morphologically and immunophenotypically similar to ALK+ ALCL, except for ALK expression, but has distinctive molecular features.
  • PTCL, not otherwise specified (PTCL, NOS), the largest PTCL category, which is derived from activated CD4+ (or CD8+) T cells, is markedly heterogeneous, including at the molecular level.
  • Gene expression profiling approaches have identified novel biomarkers of potential therapeutic interest, and suggest the existence of molecularly distinct PTCL, NOS subgroups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074096.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Markou K, Goudakos J, Constantinidis J, Kostopoulos I, Vital V, Nikolaou A: Primary laryngeal lymphoma: report of 3 cases and review of the literature. Head Neck; 2010 Apr;32(4):541-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary laryngeal lymphoma: report of 3 cases and review of the literature.
  • BACKGROUND: Extranodal lymphomas limited to the larynx are rare, accounting for less than 1% of all laryngeal neoplasms.
  • METHODS: The case records of 3 patients with the diagnosis of lymphoma involving the larynx were retrospectively reviewed.
  • RESULTS: The histopathological diagnosis revealed 1 case of marginal zone lymphoma mucosa-associated lymphoid tissue type, 1 case of T-lymphoblastic lymphoma, and 1 case of a rare coexistence of in situ squamous cell carcinoma with an isolated intravascular (angioimmunoblastic) lymphoma of peripheral T-cell origin.
  • CONCLUSIONS: Primary laryngeal lymphoma is a rare entity.
  • Early symptoms are subtle and nonspecific, and confirmation of the diagnosis is often difficult.
  • Because of the rarity of this tumor type, the optimal management remains controversial and it seems that should be managed not as a distinct disease entity but as an unusual presentation of non-Hodgkin lymphoma, according to the recent treatment trends.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378323.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


64. Tong H, Ren Y, Qian W, Xiao F, Mai W, Meng H, Jin J: Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol; 2009 Oct;90(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China.
  • We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI.
  • We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL.
  • In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001).
  • The estimated 1-year overall survival (OS) rates of patients with LAHS in the BMI and non-BMI groups were 5 and 49%, respectively.
  • The increased levels of lactate dehydrogenase, fasting triglycerides and beta(2)-microglobulin between the BMI and non-BMI groups were not significantly different, but ferritin increased significantly and liver dysfunction-related diseases were seen more in the BMI group.
  • The estimated 2-year OS rate of the 67 patients with BMI, who did not lose to follow-up, was 22%, compared with 38% in the non-BMI group.
  • The estimated 2-year OS rate of patients treated by CHOP regimen was 9%, compared with 51% of those with intensive chemotherapy, with a significant difference (log rank P = 0.0008).
  • The median survival time of the 14 patients subjected to chemotherapy combined with L: -asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days.
  • We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis.
  • BMI without lymphadenopathy is a patent clinical feature in most PTCLs.
  • Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Lymphohistiocytosis, Hemophagocytic / drug therapy. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology


65. Valbuena JR, Rassidakis GZ, Lin P, Atwell C, Georgakis GV, Younes A, Jones D, Medeiros LJ: Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol; 2005 Oct;18(10):1343-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of heat-shock protein-90 in non-Hodgkin's lymphomas.
  • Heat-shock protein-90 (HSP90) inhibitors are currently being used in phase I clinical trials for treating patients with a variety of neoplasms including lymphomas.
  • Using immunohistochemical methods, we assessed for HSP90 expression in 412 cases of non-Hodgkin's lymphoma.
  • In B-cell lymphomas, HSP90 was moderately to strongly expressed in all cases of Burkitt's lymphoma (5/5, 100%), and in subsets of follicular lymphoma (17/28, 61%), diffuse large B-cell lymphoma (27/46, 59%), nodal marginal zone B-cell lymphoma (6/16, 38%), plasma cell neoplasms (14/39, 36%), small lymphocytic lymphoma/chronic lymphocytic leukemia (3/9, 33%), mantle cell lymphoma (12/38, 32%) and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (3/10, 30%).
  • HSP90 was weakly expressed in six of 14 (43%) cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • In T-cell lymphomas, HSP90 was moderately to strongly expressed in subsets of anaplastic large-cell lymphoma (14/24, 58%; 9/12 ALK+ and 5/12 ALK-), precursor-T-cell lymphoblastic leukemia/lymphoma (20/65, 31%), unspecified peripheral T-cell lymphoma (8/43, 23%) and angioimmunoblastic T-cell lymphoma (2/17, 12%).
  • We conclude that HSP90 is commonly expressed in a subset of many types of B- and T-cell lymphoma.
  • These data suggest that many lymphoma types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for lymphoma patients.
  • [MeSH-major] HSP90 Heat-Shock Proteins / biosynthesis. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, T-Cell / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056252.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins
  •  go-up   go-down


66. Basu D, Bundele M: Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma obscured by concomitant florid epithelioid cell granulomatous reaction--a case report.
  • Epithelioid cell granuloma occurs in association with many neoplasms including lymphoma.
  • However they have rarely obscured the microscopic features of a lymphoma.
  • We report on a case where a florid epithelioid cell granulomatous reaction caused difficulty in interpretation and delayed the final diagnosis of a case of peripheral T cell lymphoma of the angioimmunoblastic type.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Diagnosis, Differential. Epithelioid Cells / pathology. Granuloma / pathology. Humans. Immunoblastic Lymphadenopathy / pathology. Lymphadenitis / diagnosis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366110.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


67. Coca Díaz F, García Alhambra Mde L, Rada Martínez S, Menárguez J, Serra Rexach JA: [Angioimmunoblastic lymphoma in a 73-year-old woman]. Rev Esp Geriatr Gerontol; 2008 Mar-Apr;43(2):117-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic lymphoma in a 73-year-old woman].
  • [Transliterated title] Linfoma angioinmunoblástico en anciana de 73 años.
  • We describe the case of a 73-year-old woman with constitutional disorder and pain in the lower limbs, leading to initial suspicion of multiple myeloma.
  • After a fulminant clinical course for a few days, the patient died, and a postmortem diagnosis of angioimmunoblastic lymphoma was established.
  • We review the main aspects of this highly infrequent disease, the pathogenesis of which remains uncertain.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682123.001).
  • [ISSN] 0211-139X
  • [Journal-full-title] Revista española de geriatría y gerontología
  • [ISO-abbreviation] Rev Esp Geriatr Gerontol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


68. Amarapurkar DN, Patel ND: Spectrum of autoimmune liver diseases in western India. J Gastroenterol Hepatol; 2007 Dec;22(12):2112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of autoimmune liver diseases in western India.
  • BACKGROUND AND AIM: The prevalence and spectrum of autoimmune liver diseases (AILDs) in India are rarely reported in comparison to the West.
  • METHOD: During a study period of 7 years, all patients with chronic liver diseases (CLDs) were evaluated for the presence of AILDs on the basis of clinical, biochemical, imaging, serological, and histological characteristics.
  • RESULTS: Of a total of 1760 CLD patients (38.1% females), 102 patients (5.7%) had an AILD.
  • A total of 75 (11.2%) female patients had an AILD.
  • Among males, 27 (2.4%) had an AILD.
  • The prevalence of AILDs in women increased from 11.2% to 45.7% and in men from 2.4% to 10.3%, after excluding alcohol, hepatitis B virus, and hepatitis C virus as a cause of CLD.
  • Of the AILDs, autoimmune hepatitis (AIH) was present in 79 patients (77.4%), followed in descending order by primary biliary cirrhosis (PBC) in 10 patients (9.8%), PBC/AIH true overlap syndrome in six patients (5.8%), primary sclerosing cholangitis (PSC) in five patients (4.9%), and PBC/AIH switchover syndrome in two patients (1.9%).
  • Associated known autoimmune diseases were found in 40 (39.2%) patients.
  • CONCLUSIONS: AILDs are not uncommon in India.
  • They should be suspected in all cases of CLDs, especially in middle-aged women who do not have problems with alcoholism and who are without viral etiology, as well as in all patients with known autoimmune diseases.
  • [MeSH-major] Autoimmune Diseases / epidemiology. Liver Diseases / epidemiology


69. Bourdi M, Eiras DP, Holt MP, Webster MR, Reilly TP, Welch KD, Pohl LR: Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol; 2007 Feb;20(2):208-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Male C57Bl/6 wild type (WT) and mice deficient in one or more cytokines were treated with 120 mg/kg APAP.
  • IL-6 appeared to have a causal role in controlling the unique susceptibility of IL-10/4-/- mice to APAP-induced liver disease (AILD) because IL-6 neutralizing antibody reversed the high sensitivity of these mice to AILD.
  • Moreover, IL-10/4/6-/- mice were also resistant to the enhanced susceptibility to AILD and expressed relatively low levels of most proinflammatory factor genes that were elevated in the IL-10/4-/- mice.
  • In conclusion, liver homeostasis following AILD appears to be highly dependent on the activities of both IL-10 and IL-4, which together help prevent overexpression of IL-6 and other potential hepatotoxic factors.
  • [MeSH-major] Acetaminophen / toxicity. Disease Models, Animal. Drug-Induced Liver Injury / metabolism. Interleukin-10 / deficiency. Interleukin-4 / deficiency. Interleukin-6 / physiology
  • [MeSH-minor] Animals. Antibodies / pharmacology. Arginase / antagonists & inhibitors. Arginase / biosynthesis. Biomarkers / blood. Genetic Predisposition to Disease. Glutathione / drug effects. Glutathione / metabolism. Interferons / biosynthesis. Liver / drug effects. Liver / metabolism. Liver / pathology. Mice. Mice, Knockout. Nitric Oxide / biosynthesis. Nitric Oxide / blood

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305405.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 31C4KY9ESH / Nitric Oxide; 362O9ITL9D / Acetaminophen; 9008-11-1 / Interferons; EC 3.5.3.1 / Arginase; GAN16C9B8O / Glutathione
  •  go-up   go-down


70. Geissinger E, Bonzheim I, Krenács L, Roth S, Ströbel P, Ott G, Reimer P, Wilhelm M, Müller-Hermelink HK, Rüdiger T: Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies. J Mol Diagn; 2005 Oct;7(4):455-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies.
  • Most nodal peripheral T-cell lymphomas (PTCL) originate from alphabeta-T cells, and they often contain reactive T cells that may hamper immunophenotyping.
  • To specifically identify the neoplastic population in immunohistochemically stained slides, we assessed the heterogeneity of the T-cell receptor beta chain variable region (TCRVbeta).
  • The TCRVbeta segment of the tumor cells was defined in 13 of 13 PTCL not otherwise specified and 11 of 13 angioimmunoblastic T-cell lymphomas.
  • [MeSH-major] Antibodies / immunology. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / pathology. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Histopathology. 1988 Jul;13(1):19-41 [3061921.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):152-8 [2464922.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):723-9 [2852027.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1093-9 [2161617.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1117-25 [2227919.001]
  • [Cites] Cancer. 1991 May 15;67(10):2566-78 [1826629.001]
  • [Cites] Eur J Haematol. 1991 Sep;47(3):168-73 [1915799.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Blood. 2000 Jul 15;96(2):640-6 [10887129.001]
  • [Cites] Cytometry. 2000 Aug 1;40(4):336-45 [10918284.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2020-7 [10925285.001]
  • [Cites] J Immunol Methods. 2000 Dec 1;246(1-2):131-43 [11121554.001]
  • [Cites] J Histochem Cytochem. 2001 Feb;49(2):139-45 [11156682.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1851-7 [11337383.001]
  • [Cites] Mol Diagn. 2001 Sep;6(3):169-79 [11571710.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):52-65 [11790533.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Pathol Res Pract. 2002;198(6):389-95 [12166895.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):785-94 [14608907.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Blood. 1986 Feb;67(2):474-8 [3080041.001]
  • [Cites] Blood. 1986 Sep;68(3):663-7 [2943330.001]
  • [Cites] Am J Pathol. 1987 Jul;128(1):181-201 [3111266.001]
  • [Cites] Br J Haematol. 1987 Aug;66(4):451-60 [3499166.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):19-24 [3499172.001]
  • [Cites] Cancer. 1988 May 15;61(10):2060-70 [2896068.001]
  • [Cites] Blood. 1988 Aug;72(2):413-21 [3261178.001]
  • [Cites] Nature. 1988 Aug 4;334(6181):395-402 [3043226.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):186-91 [1730511.001]
  • [Cites] Eur J Immunol. 1992 Feb;22(2):541-9 [1311263.001]
  • [Cites] J Pathol. 1992 Feb;166(2):109-12 [1560311.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):141-9 [1314007.001]
  • [Cites] Cancer. 1992 May 15;69(10):2571-82 [1568182.001]
  • [Cites] Hum Immunol. 1992 Sep;35(1):60-7 [1478894.001]
  • [Cites] Leuk Lymphoma. 1992 Aug;7(5-6):449-55 [1493445.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):396-412 [8372685.001]
  • [Cites] Immunol Today. 1993 Aug;14(8):391-4 [8397778.001]
  • [Cites] Leukemia. 1994 Feb;8(2):295-8 [8309253.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 1994;425(1):25-32 [7921409.001]
  • [Cites] Hum Immunol. 1995 Jul;43(3):207-18 [7558938.001]
  • [Cites] Immunogenetics. 1995;42(6):451-3 [8550091.001]
  • [Cites] Immunogenetics. 1995;42(6):455-500 [8550092.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):610-7 [9576581.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23709-15 [9726977.001]
  • [Cites] Hum Pathol. 1999 Jan;30(1):48-53 [9923926.001]
  • [Cites] J Immunol Methods. 1999 Apr 22;224(1-2):203-8 [10357220.001]
  • [Cites] Leukemia. 1999 Jun;13(6):965-74 [10360387.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Br J Dermatol. 1995 Dec;133(6):978-82 [8547055.001]
  • [Cites] Science. 1996 Jun 21;272(5269):1755-62 [8650574.001]
  • [Cites] Science. 1996 Jul 5;273(5271):104-6 [8658175.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):148-53 [8817091.001]
  • [Cites] Auris Nasus Larynx. 1997 Apr;24(2):199-206 [9134144.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Mol Pathol. 1997 Feb;50(1):15-7 [9208808.001]
  • (PMID = 16237215.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Receptors, Antigen, T-Cell, alpha-beta
  • [Other-IDs] NLM/ PMC1885558
  •  go-up   go-down


71. Jones D: Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection. Semin Hematol; 2010 Apr;47 Suppl 1:S1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional classification of peripheral T-cell lymphomas as an approach to improve outcome prediction and therapy selection.
  • Many types of peripheral T-cell lymphoma (PTCL) are currently classified by the World Health Organization (WHO) based on their predominant site of organ involvement (eg, intestinal or cutaneous types).
  • However, this approach and traditional staging scores such as the IPI can provide limited prognostic information, especially in those PTCL types where morbidity and mortality are primarily related to immune dysregulation and cytokine syndromes driven by the lymphoma cells.
  • These "immune participatory" PTCLs (including, commonly, angioimmunoblastic T-cell lymphoma and many extranodal types) can therefore have poor outcomes even at low tumor burdens.
  • For these reasons, a classification that includes functional profiling of the lymphoma cells may add valuable prognostic information.
  • Such data, including cytokine expression patterns and T-cell receptor signaling pathway activation status, whether normal or abnormal, need to be considered in future classification systems, especially when incorpating targeted therapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification
  • [MeSH-minor] Cell Differentiation. Humans. Leukemia-Lymphoma, Adult T-Cell / classification. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / classification. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Lymphoproliferative Disorders / classification. Lymphoproliferative Disorders / pathology. Prognosis. Receptors, Antigen, T-Cell / immunology. T-Lymphocytes / pathology. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359579.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 13
  •  go-up   go-down


72. Dunleavy K: Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity. Onkologie; 2008 Oct;31(10):509-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma (AILT): a unique clinical and pathobiological entity.
  • [MeSH-major] Cardiac Tamponade / diagnosis. Cardiac Tamponade / etiology. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma / complications. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2008 Oct;31(10):546-8 [18854655.001]
  • (PMID = 18854648.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


73. Xie JL, Zhou XG: Infectious mononucleosis-like lesions, a rare manifestation of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2010 May;51(5):944-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious mononucleosis-like lesions, a rare manifestation of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / diagnosis. Immunoblastic Lymphadenopathy / diagnosis. Infectious Mononucleosis / diagnosis. Lymphoma, T-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350275.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


74. Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol; 2006;116(2):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
  • We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL).
  • All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years.
  • The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT).
  • Thus, our regimen appears to be effective for high-risk AILT and SPTCL.
  • However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy


75. Longhi MS, Mitry RR, Samyn M, Scalori A, Hussain MJ, Quaglia A, Mieli-Vergani G, Ma Y, Vergani D: Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology; 2009 Jul;50(1):130-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells.
  • Studies in AIH have focused on autoreactive CD4 and CD8 T cells and impairment of CD4+CD25+ regulatory T cells (T-regs), whereas little is known about the role of monocytes and their relationship with T-regs.
  • We have investigated 51 patients with autoimmune liver disease (AILD) and 27 healthy subjects, finding that monocytes were higher in number (P = 0.044), had a more vigorous spontaneous migration (P < 0.0005 in patients with inactive disease [ID], and P < 0.001 in those with active disease [AD]), displayed a higher tumor necrosis factor alpha (TNF-alpha) over interleukin (IL)-10 production (P = 0.07 in ID and P = 0.0005 in AD), and expressed higher levels of Toll-like receptor (TLR) 4 (P = 0.048 in ID and P = 0.03 in AD).
  • Addition of conventional T-regs (cT-regs) in AILD enhanced monocyte migration (P = 0.05 in ID and P = 0.08 in AD), magnified TNF-alpha over IL-10 production (P = 0.0005 in ID and P = 0.006 in AD), and markedly increased TLR4 expression levels (P = 0.01 in ID and P = 0.004 in AD), whereas in normal subjects it either restrained or left unchanged monocyte function.
  • Addition of tT-regs to monocytes decreased monocyte migration (P = 0.03) and promoted IL-10 production (P = 0.009), leaving unchanged TLR4 expression in healthy subjects, whereas in patients with AILD it induced only a marginal increase in IL-10 production (P = 0.045 in ID and P = 0.13 in AD).
  • CONCLUSION: Monocyte overactivation and inability of cT-regs and tT-regs to restrain it may contribute to the loss of immune tolerance and perpetuation of the autoimmune attack in AILD.
  • [MeSH-major] Autoimmune Diseases / immunology. Leukocytes, Mononuclear / physiology. Liver Diseases / immunology. T-Lymphocytes, Regulatory / physiology

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437492.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Zhang D, Saunders CJ, Zhao W, Davis M, Cunningham MT: The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia. Am J Hematol; 2009 Sep;84(9):606-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia.
  • T cells coexpressing CD3 and CD10 are a characteristic feature of angioimmunoblastic T-cell lymphoma (AITL) [1].
  • However, they are not unique to AITL, as these cells are also present in B cell lymphoma and reactive lymphoid hyperplasia [2].
  • To determine the significance of CD3+ CD10+ T cells, we used flow cytometry with cell sorting and molecular biology techniques for T cell gene rearrangement to study T cells from patients with AITL, B cell lymphoma, and reactive lymph node hyperplasia.
  • We found that CD3+ CD10+ T cells in B cell lymphoma and reactive lymphoid hyperplasia were polyclonal.
  • These findings illustrate the differences between early and late lymphoma and could be important for the diagnosis of AITL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Pseudolymphoma / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Clone Cells. Humans. Immunoblastic Lymphadenopathy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650143.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


77. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M: Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol; 2008 Sep;26(3):152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
  • We studied the clinico-pathologic features and treatment outcome of patients with peripheral T-cell lymphoma (PTCL).
  • This study included 215 patients with T/natural killer (NK)-cell lymphoma, including 59 with PTCL-unspecified (PTCL-U), 42 with angioimmunoblastic T-cell lymphoma (AILT) and 20 with anaplastic large-cell lymphoma (ALCL).
  • Most of the analyses were performed on patients with AILD, ALCL and PTCL-U.
  • The patients with AILT and PTCL-U tended to be older than those with ALCL.
  • Stage III/IV disease was seen in 90.5% of the AILT cases, 55% of the ALCL cases and 67.8% of the PTCL-U cases.
  • In addition, 61.9% of the AILT cases had an international prognostic index (IPI) of H-I or H risk.
  • The 5-year progression-free survival (PFS) and overall survival (OS) rates were 72.2 and 76.1% among the ALCL cases, 40.7 and 42.2% among the PTCL-U cases and 31.2 and 49.3% among the AILT cases, respectively.
  • The 5-year PFS and OS rates among patients who received CHOP therapy, CyclOBEAP [cyclophosphamide (CPA), vincristine (VCR), bleomycine, etoposide, doxorubicin (DXR), prednisone (PDN)] therapy or autologous stem cell transplantation were: 22 and 25.7%, 59 and 61.7% or 33.3 and 60%, respectively.
  • PTCL-U is a heterogeneous disease with regard to histological type and pathological state.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18395866.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


78. Choi JH, Oh YH, Park IK: A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. Cancer Res Treat; 2010 Jun;42(2):115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • Pure red cell aplasia is a bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leucopenia and thrombocytopenia.
  • It is associated with various hematologic diseases.
  • However, pure red cell aplasia with angioimmunoblastic T cell lymphoma has rarely been reported.
  • Here we describe a 43-year-old woman with pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma.
  • A CT scan of the abdomen revealed marked hepatosplenomegaly and small multiple lymphadenopathies.
  • A bone marrow biopsy revealed focal infiltration of abnormal lymphoid cells and absence of red cell precursors.
  • Splenic biopsy was compatible with angioimmunoblastic T-cell lymphoma.
  • Ultimately, diagnosis of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma was made.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1996;96(2):68-72 [8701703.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):72-8 [8172198.001]
  • [Cites] J R Soc Med. 1983 Oct;76(10):894-5 [6631867.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):259-60 [10589086.001]
  • [Cites] Biomed Pharmacother. 2003 Oct;57(8):326-32 [14568226.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] Haematologica. 1982 Nov-Dec;67(6):919-25 [6819197.001]
  • (PMID = 20622966.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901080
  • [Keywords] NOTNLM ; Lymphoma / Pure / Red-cell aplasia / T-cell
  •  go-up   go-down


79. Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabeçadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol; 2007 Jul;31(7):1077-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.
  • Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, but aggressive nodal peripheral T-cell lymphoma.
  • Eleven cases where polymerase chain reaction results for T-cell receptor-gamma gene rearrangement were directly compared showed an identical band-size in the initial and follow-up biopsies.
  • Seven cases (23%) developed EBV-associated B-cell lymphomas [5 diffuse large B-cell lymphoma (DLBCL) and 2 classic Hodgkin lymphoma].
  • In 4 cases, a dominant B-cell clone was observed in biopsies lacking evidence of DLBCL.
  • A single case was complicated by EBV-negative DLBCL, whereas another with large cell transformation had a T-cell phenotype.
  • In conclusion, AITL represents a clonal T-cell proliferation with a stable T-cell clone throughout the disease.
  • When "morphologic high-grade transformation" occurs, it is usually due to a secondary (often EBV-associated) B-cell lymphoma, rather than a T-cell neoplasm.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Clone Cells / metabolism. Clone Cells / pathology. Disease Progression. Disease-Free Survival. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. RNA, Viral / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592275.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


80. Leich E, Haralambieva E, Zettl A, Chott A, Rüdiger T, Höller S, Müller-Hermelink HK, Ott G, Rosenwald A: Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. J Pathol; 2007 Sep;213(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas.
  • The pathogenesis of mature T-cell non-Hodgkin lymphomas (T-NHLs) is poorly understood.
  • Analogous to B-cell lymphomas, in which the immunoglobulin (IgH) receptor loci are frequently targeted by chromosomal translocations, the T-cell receptor (TCR) gene loci are affected by translocations in a subset of precursor T-cell malignancies.
  • In a large-scale analysis of 245 paraffin-embedded mature T-NHLs, arranged in a tissue microarray format and using improved FISH assays for the detection of breakpoints in the TCRalpha/delta, TCRbeta, and TCRgamma loci, we provide evidence that mature T-NHLs other than T-cell prolymphocytic leukaemia (T-PLL) also occasionally show a chromosomal rearrangement that involves the TCRalpha/delta locus.
  • In particular, one peripheral T-cell lymphoma (not otherwise specified, NOS) with the morphological variant of Lennert lymphoma displayed a chromosomal translocation t(14;19) involving the TCRalpha/delta and the BCL3 loci.
  • A second case, an angio-immunoblastic T-cell lymphoma (AILT), carried an inv(14)(q11q32) affecting the TCRalpha/delta and IgH loci.
  • FISH signal constellations as well as concomitant comparative genomic hybridization (CGH) data were also suggestive of the occurrence of an isochromosome 7, previously described to be pathognomonic for hepatosplenic T-cell lymphomas, in rare cases of enteropathy-type T-cell lymphoma.
  • [MeSH-major] Chromosome Breakage. Gene Rearrangement, T-Lymphocyte. Genes, T-Cell Receptor. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Case-Control Studies. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 19. Chromosomes, Human, Pair 7. Gene Expression Profiling. Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Oligonucleotide Array Sequence Analysis. Paraffin Embedding. Proto-Oncogene Proteins / genetics. Transcription Factors / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582237.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / proto-oncogene protein bcl-3
  •  go-up   go-down


81. Miura N, Suzuki K, Yoshino M, Kitagawa W, Yamada H, Ohtani H, Joh K, Imai H: Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma. Am J Kidney Dis; 2006 Jul;48(1):e3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma.
  • A 70-year-old man with angioimmunoblastic T-cell lymphoma developed acute renal failure.
  • These findings suggest that cryoglobulin, which consists of monoclonal IgM-lambda, induced glomerular thrombi and acute renal failure in a patient with angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Thrombosis / etiology. Thrombosis / immunology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797380.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


82. Tajika K, Tamai H, Mizuki T, Nakayama K, Yamaguchi H, Dan K: [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2010 Feb;51(2):138-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma].
  • We report here a rare case of EBV-related post-transplantation lymphoproliferative disorder (PTLD) localized to the skin.
  • The patient was a 64-year-old man diagnosed with angioimmunoblastic T cell lymphoma (AITL).
  • He underwent cord blood transplantation with a reduced intensity conditioning regimen during partial remission after chemotherapy.
  • Chimerism analysis revealed that the tumor cells were derived from donor cells, which led to the diagnosis of EBV-related PTLD.
  • [MeSH-major] Fetal Blood / transplantation. Herpesvirus 4, Human. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy. Lymphoproliferative Disorders / virology. Skin Diseases / virology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379106.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


83. Dunleavy K, Wilson WH: Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma; 2010 Sep;51(9):1583-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Glycoproteins / antagonists & inhibitors. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2010 Jul;51(7):1347-50 [20572801.001]
  • (PMID = 20795788.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


84. Willenbrock K, Renné C, Gaulard P, Hansmann ML: In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch; 2005 Jan;446(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study.
  • The significance of T-cell proliferations in angioimmunoblastic lymphoma (AILD) is still enigmatic.
  • Although classified as a malignant T-cell lymphoma in the World Health Organisation lymphoma classification, some cases of AILD lack dominant T-cell clones.
  • In a previous study, based on single-cell polymerase chain reaction (PCR), we obtained similar results as studies of AILD using Southern blot or conventional PCR: some cases of AILD contained large T-cell clones, and, in other cases, T-cell clones were undetectable.
  • As in single-cell studies, only a limited number of cells could be investigated; thus, we wanted to gain more insight into the amount and distribution of tumour cells.
  • By applying triple immunofluorescent staining with antibodies directed against T-cell receptor Vbeta-family-specific epitopes, we investigated T-cell populations in AILD and their localisation in the tissue in relation to B cells (CD20) and follicular dendritic cells (CD21).
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Lymphoma, T-Cell / immunology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD20 / analysis. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Polymerase Chain Reaction. Receptors, Antigen, T-Cell, alpha-beta / analysis. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):541-5 [10953975.001]
  • [Cites] N Engl J Med. 1975 Jan 2;292(1):1-8 [1078547.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1067-71 [10702422.001]
  • [Cites] Blood. 1995 May 15;85(10):2862-9 [7742548.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1851-7 [11337383.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;406(1):105-24 [3922106.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4955-67 [8262038.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Eur J Immunol. 1998 Aug;28(8):2424-31 [9710220.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Leukemia. 1997 Jul;11(7):1055-62 [9204991.001]
  • [Cites] Lancet. 1974 Jun 1;1(7866):1070-3 [4135245.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):392-7 [3082212.001]
  • [Cites] Dtsch Med Wochenschr. 1975 May 23;100(21):1157-63 [1132324.001]
  • (PMID = 15480765.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Complement 3d
  •  go-up   go-down


85. Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N: The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma; 2005 Jul;46(7):999-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
  • Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets.
  • We examined the effect of thalidomide on T-lymphocyte subsets in 18 patients with MDS, 6 patients with MM, 4 patients with IM, and 3 patients with angioimmunoblastic lymphoma (AILD).
  • These patients had either a relapse or progressive disease following cytotoxic chemotherapy including high-dose chemotherapy with autologous stem cell support.
  • T-lymphocyte subsets (CD4+, CD8+) were measured by fluorescence-activated cell sorter (FACS) before and during treatment with thalidomide.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. CD4-CD8 Ratio. Hematologic Diseases / drug therapy. Immunosuppressive Agents / therapeutic use. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019550.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


86. Wang FX, Zhang XJ, Pan L, Qiao SK, Guo XL, Dong ZR: [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):862-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia].
  • Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell lymphoma often complicated autoimmune phenomena such as autoimmune cytopenia, and is a truly rare type of NHL.
  • In order to investigate the clinical features, pathological manifestation of this lymphoma, and to explore its therapy protocol, a 37-years old patient with AILT was investigated.
  • The warm type autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) were co-existed.
  • In conclusion, the AITL patient complicated with AIHA and PRCA was successfully diagnosed, the lymphonode biopsy and bone marrow smear showed more significant, the chemotherapy protocol of CHOP-E can give some effect to cure such angioimmunoblastic T cell lymphoma.


87. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K: Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int; 2008 Feb;58(2):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.
  • Although various CD markers have been analyzed in T-cell and natural killer (NK)-cell lymphomas, the sensitivity and specificity of these phenotypic features have not been satisfactorily characterized.
  • Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56).
  • In data obtained from 319 patients, CD10 expression was detected in 57% of angioimmunoblastic T-cell lymphomas, CD30 in 93% of anaplastic large cell lymphomas, CD34 in 50% of lymphoblastic lymphomas, and CD56 in 100% of extranodal NK/T-cell lymphomas nasal type.
  • A total of 92% of adult T-cell leukemia/lymphomas (ATLL) had expression of CD25 and downregulation of CD7.
  • Of special interest is that 92 ATLL (50%) were CD4+CD7-CD25+ phenotype while only four peripheral T-cell lymphoma unspecified (9%) and one (9%) cutaneous T-cell lymphoma had this phenotype.
  • Phenotypic analysis using FCM was thus found to be useful for differential diagnosis of T-cell and NK-cell lymphomas.
  • [MeSH-major] Flow Cytometry / methods. Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunophenotyping. Lymph Nodes / immunology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199158.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


88. de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol; 2010 Mar;148(5):673-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma (PTCL) entity with peculiar clinical and pathological features.
  • The recent identification of follicular helper T (T(FH)) cell as the cell of origin of this neoplasm represents a major step in our understanding of the pathobiological characteristics of the disease and should, in the future, clarify the diagnostic criteria for AITL and help to delineate its spectrum, especially from PTCL, not otherwise specified (PTCL, NOS).
  • Deciphering the pathogenesis of the disease is needed to identify targets for new therapies that are expected to improve the poor outcome of AITL patients, when treated with conventional chemotherapy regimens.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / physiopathology
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cytogenetics. Diagnosis, Differential. Humans. Immunophenotyping. Prognosis. T-Lymphocytes, Helper-Inducer / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961485.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 170
  •  go-up   go-down


89. Bal M, Gujral S, Gandhi J, Shet T, Epari S, Subramanian PG: Angioimmunoblastic T-Cell lymphoma: a critical analysis of clinical, morphologic and immunophenotypic features. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):640-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-Cell lymphoma: a critical analysis of clinical, morphologic and immunophenotypic features.
  • BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL), a subtype of peripheral T-cell lymphoma (PTCL), is characterized by unique clinical and biological features.
  • Its diagnosis remains a challenge as clinical presentation as well as pathologic findings are frequently misleading.
  • Common clinical features included generalized lymphadenopathy (60%), hepatomegaly (70%), splenomegaly (50%), anemia (80%) and polyclonal hypergammaglobulinemia (100%).
  • Absence of follicles, polymorphous infiltrate, extra-follicular follicular dendritic cell (FDC) proliferation, high endothelial venules (HEV) prominence and neoplastic T-cells were the diagnostic features of AITL.
  • CONCLUSION: Awareness of various morphological and immunophenotypic complexities of AITL and distinction from reactive adenopathies and other types of lymphomas that mimic AITL is underscored in this study.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / diagnosis. Anemia / etiology. Antigens, CD20 / analysis. Female. Hepatomegaly / diagnosis. Hepatomegaly / etiology. Histocytochemistry. Humans. Hypergammaglobulinemia / diagnosis. Hypergammaglobulinemia / etiology. Immunohistochemistry. Lymphatic Diseases / diagnosis. Lymphatic Diseases / etiology. Male. Microscopy. Middle Aged. Neprilysin / analysis. Retrospective Studies. Sex Distribution. Splenomegaly / diagnosis. Splenomegaly / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045384.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


90. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, Vetri V, Pucillo CE, Florena AM, Colombo MP, Pileri SA: Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol; 2010 Aug;177(2):792-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.
  • Reports focusing on the immunological microenvironment of peripheral T-cell lymphomas (PTCL) are rare.
  • Here we studied the reciprocal contribution of regulatory (Treg) and interleukin-17-producing (Th17) T-cells to the composition of the lymphoma-associated microenvironment of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified on tissue microarrays from 30 PTCLs not otherwise specified and 37 AITLs.
  • We found that Th17 but not Treg cells were differently represented in the two lymphomas and correlated with the amount of mast cells (MCs) and granulocytes, which preferentially occurred in the cellular milieu of AITL cases.
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Inflammation / immunology. Lymphoma, T-Cell / immunology. Mast Cells / immunology. Th17 Cells / immunology. Tumor Microenvironment

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Annu Rev Immunol. 2008;26:705-39 [18370925.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):478-86 [18483499.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Am J Clin Pathol. 2008 Oct;130(4):613-9 [18794055.001]
  • [Cites] Nat Immunol. 2008 Nov;9(11):1215-23 [18936782.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71 [18684638.001]
  • [Cites] Immunity. 2008 Nov 14;29(5):771-81 [18993084.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:272-9 [19074096.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1 Suppl 1:S43-6 [19079228.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1246-54 [19056856.001]
  • [Cites] Haematologica. 2009 Jan;94(1):127-30 [19029148.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):92-107 [19119024.001]
  • [Cites] Immunity. 2009 Mar 20;30(3):324-35 [19303387.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):239-52 [19279573.001]
  • [Cites] Nat Rev Rheumatol. 2009 Jun;5(6):325-31 [19434074.001]
  • [Cites] Curr Opin Immunol. 2009 Jun;21(3):274-80 [19524429.001]
  • [Cites] Am J Hematol. 2009 Jul;84(7):435-8 [19484731.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5619-22 [19567669.001]
  • [Cites] Blood. 2009 Aug 6;114(6):1141-9 [19470694.001]
  • [Cites] Immunobiology. 2009;214(9-10):835-42 [19628296.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] N Engl J Med. 2009 Aug 27;361(9):888-98 [19710487.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4197-203 [19636021.001]
  • [Cites] J Immunol. 2009 Oct 1;183(7):4169-75 [19767566.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2639-48 [19643985.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2936-44 [19671921.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Nov;72(2):125-43 [19233683.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):79-87 [19740519.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Trends Immunol. 2010 Mar;31(3):97-102 [20149743.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2810-7 [20101023.001]
  • [Cites] Br J Haematol. 2010 Mar;148(5):673-89 [19961485.001]
  • [Cites] J Rheumatol. 2000 Apr;27(4):1087-90 [10782842.001]
  • [Cites] J Pathol. 2003 Feb;199(2):201-7 [12533833.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3037-45 [12626558.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Lab Invest. 2004 Nov;84(11):1512-9 [15311211.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1504-8 [8751470.001]
  • [Cites] Acta Haematol. 2005;114(2):108-12 [16103635.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • (PMID = 20595635.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL13; 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-17; 0 / Interleukin-6
  • [Other-IDs] NLM/ PMC2913370
  •  go-up   go-down


91. Oka K, Nagayama R, Yatabe Y, Iijima S, Mori N: Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases. Pathol Res Pract; 2010 Apr 15;206(4):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases.
  • We report two patients, a 68-year-old man (Case 1) and a 66-year-old man (Case 2), with polyclonal gammopathy, lymphadenopathy, thrombocytopenia, and high platelet-associated IgG (PAIgG) level.
  • We initially diagnosed them as having angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
  • From confirmation of clear cells by careful observation and detection of rearrangement bands of T cell receptors by Southern blot hybridization analysis, we finally concluded that their diagnoses were compatible with angioimmunoblastic T-cell lymphoma (AILT).
  • AILT with autoimmune thrombocytopenia (AIT) is very rare, and all the reported cases were Japanese ones.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / pathology. Purpura, Thrombocytopenic, Idiopathic / pathology
  • [MeSH-minor] Aged. Blotting, Southern. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19442454.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Kojima M, Sugiura I, Itoh H, Shimizu K, Murayama K, Motoori T, Shimano S, Masawa N, Nakamura S: Histological varieties of Epstein-Barr virus-related lymph node lesion resembling autoimmune disease-like clinicopathological findings in middle-aged and elderly patients: a study of six cases. Pathol Res Pract; 2006;202(8):609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological varieties of Epstein-Barr virus-related lymph node lesion resembling autoimmune disease-like clinicopathological findings in middle-aged and elderly patients: a study of six cases.
  • Six cases were studied to further clarify clinicopathological findings of Epstein-Barr virus (EBV)-related lymph node lesions showing autoimmune disease-like clinicopathological findings (EBVAID) in middle-aged and elderly patients.
  • The patients, four males and two females, ranged in age from 53 to 74 years, with a median age of 62 years.
  • Clinically, they were characterized by systemic lymphadenopathy, "B"symptoms, polyclonal hypergammaglobulinemia, elevated serum lactate dehydrogenase and a transient presence of various autoantibodies, as well as an infrequent presence of atypical lymphocytosis in peripheral blood.
  • Histologically, three patterns could be delineated: pattern A, follicular hyperplasia with pronounced arborizing vasculature in the expanded paracortex (n=3); pattern B, follicular hyperplasia with pronounced interfollicular B-immunoblastic/plasma cell proliferation (n=2); and pattern C, paracortical hyperplasia containing numerous large transformed lymphocytes (n=1).
  • Polymerase chain reaction analysis demonstrated that neither clonal rearrangement of T-cell receptor gamma-chain nor immunoglobulin heavy-chain rearrangement was detected in the three cases examined.
  • Although EBVAID appears to be rare in middle-aged and older adults, EBVAID exhibits histological variations and should be added to the differential diagnosis of various atypical or malignant lymphoproliferative disorders, in particular autoimmune-disease-associated lymphadenopathy and angioimmunoblastic T-cell lymphoma with a hyperplastic germinal center in middle-aged and elderly patients.
  • [MeSH-major] Autoimmune Diseases / pathology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Lymph Nodes / pathology. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Aged. Autoantibodies / blood. Diagnosis, Differential. Female. Humans. Hypergammaglobulinemia / complications. Hypergammaglobulinemia / pathology. Immunoenzyme Techniques. In Situ Hybridization. L-Lactate Dehydrogenase / blood. Lymphatic Diseases / complications. Lymphatic Diseases / pathology. Lymphocytosis / complications. Lymphocytosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824704.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


93. Grogg KL, Morice WG, Macon WR: Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol; 2007 Jun;137(5):416-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.
  • Bone marrow (BM) biopsy is often performed early in the evaluation of patients with angioimmunoblastic T-cell lymphoma (AITL), and may be the first diagnostic tissue sample; yet the BM histopathology associated with this disease has not been well described.
  • Seven (54%) were involved by AITL, which was characterised by paratrabecular and interstitial polymorphous infiltrates containing cytologically atypical lymphocytes, histiocytes and eosinophils.
  • As in lymph nodes, the lymphomatous infiltrate in some BMs contained numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma, respectively.
  • When BM biopsy preceded the diagnosis of AITL, these secondary changes were misinterpreted as chronic myeloproliferative disease (n = 2), or plasma cell dyscrasia (n = 2).
  • The spectrum of BM findings in AITL patients is important to recognise for early and accurate diagnosis in this disease.
  • [MeSH-major] Bone Marrow Examination. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Chemokine CXCL13. Chemokines, CXC / analysis. Diagnosis, Differential. Eosinophils / pathology. Histiocytes / pathology. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Neprilysin / analysis. Red-Cell Aplasia, Pure / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488486.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


94. Liao YL, Chang ST, Kuo SY, Lin SH, Chen CK, Chang KM, Chuang SS: Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma of cytotoxic T-cell phenotype containing a large B-cell proliferation with an undersized B-cell clonal product.
  • Angioimmunoblastic T-cell lymphoma is a nodal peripheral T-cell lymphoma considered to be derived from CD4 follicular helper T cells.
  • We presented the case of a 60-year-old male patient with angioimmunoblastic T-cell lymphoma, in which the neoplastic T cells expressed CD8, bcl-6, and programmed death-1.
  • The results of T-cell receptor gene rearrangement study using the Biomed-2 protocols showed clonal rearrangement with amplicons falling within the expected size ranges.
  • Through cloning, sequencing, and BLAST searches, we confirmed that the FR2/JH amplicon was derived from the IgH rearrangement with a deletion of a short segment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956067.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


95. Tzankov AS, Went PT, Münst S, Papadopoulos T, Jundt G, Dirnhofer SR: Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol; 2007 Jun;20(6):632-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare expression of BSAP (PAX-5) in mature T-cell lymphomas.
  • Lineage determination in lymphomas is based on the assessment of lineage-specific markers, such as the B-cell-specific activator protein of the paired box family (BSAP, PAX-5) for the B-cell lineage.
  • BSAP is thought to be expressed exclusively in B cells from the pro-B- to the mature B-cell stage and then silenced in plasma cells.
  • BSAP has oncogenic potential and experimental evidence shows that the T-cell lineage is prone to this effect.
  • Herein, we report on a BSAP-positive peripheral T-cell lymphoma with monoclonal T-cell receptor gamma-gene rearrangement.
  • To assess the relative frequency of BSAP expression in mature T-cell lymphomas, we constructed and examined a tissue microarray consisting of 43 angioimmunoblastic T-cell lymphomas and peripheral T-cell lymphomas and detected no additional BSAP-positive cases.
  • To conclude, BSAP can probably contribute to T-cell lymphomagenesis not only in vitro, but also in vivo.
  • It is rarely expressed in peripheral T-cell lymphoma, thus its detection on lymphoid malignancies cannot be considered definitively lineage specific.
  • [MeSH-major] B-Cell-Specific Activator Protein / biosynthesis. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / biosynthesis. Cell Lineage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymphoma, T-Cell, Peripheral / metabolism. Male. Middle Aged. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431414.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


96. Khong PL, Pang CB, Liang R, Kwong YL, Au WY: Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol; 2008 Aug;87(8):613-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
  • Fluorine-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is useful in Hodgkin and B-cell lymphomas.
  • Few data exist on T-cell and natural killer (NK)-cell lymphomas.
  • Thirty consecutive T-cell and NK-cell lymphomas were investigated with PET-computerized tomography (CT).
  • In 12 NK-cell lymphomas, all nasal/extranasal lesions were FDG-avid.
  • In two NK-cell lymphomas, PET did not detect morphologically occult marrow infiltration uncovered by in situ hybridisation for Epstein-Barr-virus-encoded small RNA.
  • In angioimmunoblastic lymphoma (n = 7), peripheral T-cell lymphoma, unspecified (PTCL-U, n = 4) and anaplastic large cell lymphoma (ALCL, n = 3), involved nodal/extranodal sites shown on CT and/or biopsy were concordantly PET-positive.
  • In one case of T-cell large granular lymphocyte leukaemia, marrow, nodal and bowel infiltrations were not FDG-avid.
  • These observations defined the pre-treatment value of PET-CT in T-cell and NK-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Killer Cells, Natural / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Disease Progression. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509641.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


97. Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program; 2009;:523-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.
  • Recent studies have drawn attention to the biological overlap between classical Hodgkin lymphoma (CHL) and diffuse large B-cell lymphomas (DLBCL).
  • Similarly, there is a greater appreciation of the borderlands between Burkitt lymphoma and DLBCL.
  • Among the peripheral T-cell lymphomas (PTCL), more precise definitions were introduced for several entities, including anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, and subcutaneous panniculitis-like T-cell lymphoma.
  • Several new variants of primary cutaneous T-cell lymphomas are proposed.
  • Finally, the subclassification and categorization of the most common lymphoma subtypes, follicular lymphoma (FL) and DLBCL, were altered to enhance diagnostic accuracy and aid in clinical management.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008237.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


98. Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, Delfau-Larue MH, Marafioti T, Chott A, Gaulard P: Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol; 2009 May;33(5):682-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.
  • Rare cases of peripheral T-cell lymphomas with follicular growth pattern (PTCL-F) have been recently reported, and their association with t(5;9)(q33;q22) involving ITK and SYK has been suggested.
  • However, the clinicopathologic aspects of PTCL-F are poorly described and the normal cell counterpart of this subgroup of lymphoma is still unknown.
  • Patients with clinical data available had multiple lymphadenopathies (25/28, 89%), stage III to IV diseases (17/26, 65%), B symptoms (7/27, 26%), and skin lesions (6/23, 26%).
  • Three patients with sequential biopsies disclosed clinical and histopathologic features of angioimmunoblastic T-cell lymphoma at initial presentation.
  • Our results show that this rare form of PTCL-F (1) has an immunophenotype indicative of derivation from TFH cells, (2) is associated with t(5;9) in a proportion of cases, and (3) shows some overlapping features with angioimmunoblastic T-cell lymphoma, raising the question of a possible relationship.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Follicular / pathology. Lymphoma, T-Cell, Peripheral / pathology. T-Lymphocytes, Helper-Inducer / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD4 / analysis. Antigens, Differentiation, T-Lymphocyte / analysis. Apoptosis Regulatory Proteins / analysis. Biopsy. Chemokine CXCL13 / analysis. Chromosomes, Human, Pair 5. Chromosomes, Human, Pair 9. DNA-Binding Proteins / analysis. Europe. Gene Expression Regulation, Neoplastic. Gene Rearrangement, T-Lymphocyte. Genotype. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Inducible T-Cell Co-Stimulator Protein. Middle Aged. Neoplasm Staging. Neprilysin / analysis. Phenotype. Programmed Cell Death 1 Receptor. Translocation, Genetic

  • HAL archives ouvertes. Full text from .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295409.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Apoptosis Regulatory Proteins; 0 / BCL6 protein, human; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / DNA-Binding Proteins; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4838638
  •  go-up   go-down


99. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, Yamada A, Maeda A, Matsuno F, Hata H, Suzuki A, Imagawa S, Mitsuya H, Esumi H, Koyama A, Yamamoto M, Mori N, Takahashi S: Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res; 2006 Jan 15;66(2):812-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.
  • In this study, we have found that mice transgenic for c-Maf whose expression was direct to the T-cell compartment developed T-cell lymphoma.
  • Moreover, we showed that cyclin D2, integrin beta(7), and ARK5 were up-regulated in c-Maf transgenic lymphoma cells.
  • Furthermore, 60% of human T-cell lymphomas (11 of 18 cases), classified as angioimmunoblastic T-cell lymphoma, were found to express c-Maf.
  • These results suggest that c-Maf might cause a type of T-cell lymphoma in both mice and humans and that ARK5, in addition to cyclin D2 and integrin beta(7), might be downstream target genes of c-Maf leading to malignant transformation.
  • [MeSH-major] Lymphoma, T-Cell / genetics. Proto-Oncogene Proteins c-maf / biosynthesis
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Cyclin D2. Cyclins / biosynthesis. Gene Expression Profiling. Humans. Integrin beta Chains / biosynthesis. Mice. Protein Kinases / biosynthesis. Repressor Proteins / biosynthesis. Up-Regulation

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Ccnd2 protein, mouse; 0 / Cyclin D2; 0 / Cyclins; 0 / Integrin beta Chains; 0 / MAF protein, human; 0 / Maf protein, mouse; 0 / Proto-Oncogene Proteins c-maf; 0 / Repressor Proteins; 0 / integrin beta7; EC 2.7.- / Protein Kinases; EC 2.7.1.- / NUAK1 protein, human
  •  go-up   go-down


100. Sakai H, Tanaka H, Katsurada T, Yoshida Y, Okamoto E, Ohno H: Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis. Intern Med; 2007;46(7):419-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis.
  • A 73-year-old man presented with lymphadenopathy, hepatosplenomegaly, and a variety of hematological and immunological abnormalities.
  • Circulating lymphoplasmacytic/immunoblastic cells showed an early plasma cell immunophenotype on flow cytometric analysis.
  • Combination of these observations indicated that the underlying disorder of this patient was angioimmunoblastic T-cell lymphoma (AITL); postmortem pathology was consistent with progression of peripheral T-cell lymphoma.
  • Even in the absence of definitive lymph node biopsy, the appearance of the bone marrow and the peripheral blood can lead to the diagnosis of AITL.
  • [MeSH-major] Bone Marrow / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Plasma Cells / pathology
  • [MeSH-minor] Aged. Autopsy. Biopsy, Needle. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Risk Assessment. Severity of Illness Index

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409610.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement